0001400271 2022-01-01 2022-06-30 0001400271 2021-12-31 0001400271 2020-12-31 0001400271 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001400271 us-gaap:SeriesAPreferredStockMember 2020-12-31 0001400271 us-gaap:SeriesCPreferredStockMember 2021-12-31 0001400271 us-gaap:SeriesCPreferredStockMember 2020-12-31 0001400271 2022-06-30 0001400271 us-gaap:SeriesCPreferredStockMember 2022-06-30 0001400271 us-gaap:SeriesBPreferredStockMember 2021-12-31 0001400271 us-gaap:SeriesBPreferredStockMember 2020-12-31 0001400271 us-gaap:SeriesAPreferredStockMember 2022-06-30 0001400271 us-gaap:SeriesBPreferredStockMember 2022-06-30 0001400271 2021-01-01 2021-12-31 0001400271 2020-01-01 2020-12-31 0001400271 2022-04-01 2022-06-30 0001400271 2021-04-01 2021-06-30 0001400271 2021-01-01 2021-06-30 0001400271 us-gaap:CommonStockMember 2019-12-31 0001400271 us-gaap:PreferredStockMember 2019-12-31 0001400271 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001400271 us-gaap:RetainedEarningsMember 2019-12-31 0001400271 2019-12-31 0001400271 us-gaap:CommonStockMember 2020-12-31 0001400271 us-gaap:PreferredStockMember 2020-12-31 0001400271 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001400271 us-gaap:RetainedEarningsMember 2020-12-31 0001400271 us-gaap:CommonStockMember 2021-12-31 0001400271 us-gaap:PreferredStockMember 2021-12-31 0001400271 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001400271 us-gaap:RetainedEarningsMember 2021-12-31 0001400271 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001400271 us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001400271 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001400271 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001400271 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001400271 us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001400271 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001400271 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001400271 us-gaap:CommonStockMember 2022-01-01 2022-06-30 0001400271 us-gaap:PreferredStockMember 2022-01-01 2022-06-30 0001400271 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-06-30 0001400271 us-gaap:RetainedEarningsMember 2022-01-01 2022-06-30 0001400271 us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001400271 us-gaap:PreferredStockMember 2021-01-01 2021-06-30 0001400271 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-06-30 0001400271 us-gaap:RetainedEarningsMember 2021-01-01 2021-06-30 0001400271 us-gaap:CommonStockMember 2022-06-30 0001400271 us-gaap:PreferredStockMember 2022-06-30 0001400271 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001400271 us-gaap:RetainedEarningsMember 2022-06-30 0001400271 us-gaap:CommonStockMember 2021-06-30 0001400271 us-gaap:PreferredStockMember 2021-06-30 0001400271 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001400271 us-gaap:RetainedEarningsMember 2021-06-30 0001400271 2021-06-30 0001400271 CUBT:MidAtlanticBioTheraputicsIncMember 2021-10-01 2021-12-31 0001400271 CUBT:WebsiteMember 2020-12-01 2020-12-31 0001400271 CUBT:WebsiteMember 2021-01-01 2021-12-31 0001400271 CUBT:WebsiteMember 2020-03-01 2020-03-31 0001400271 us-gaap:PatentsMember CUBT:IEMIncMember 2020-10-01 2020-10-31 0001400271 us-gaap:PatentsMember CUBT:IEMIncMember 2021-09-01 2021-09-30 0001400271 us-gaap:PatentsMember CUBT:MidAtlanticBioTheraputicsIncMember 2020-10-01 2020-10-31 0001400271 us-gaap:PatentsMember 2020-10-01 2020-10-31 0001400271 CUBT:InvestigationalNewDrugMember us-gaap:PatentsMember 2020-10-01 2020-10-31 0001400271 CUBT:InvestigationalNewDrugMember srt:MinimumMember us-gaap:PatentsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-10-01 2020-10-31 0001400271 CUBT:InvestigationalNewDrugMember srt:MaximumMember us-gaap:PatentsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-10-01 2020-10-31 0001400271 CUBT:InvestigationalNewDrugMember us-gaap:PatentsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-10-01 2020-10-31 0001400271 CUBT:InvestigationalNewDrugMember srt:MinimumMember us-gaap:PatentsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2020-10-01 2020-10-31 0001400271 CUBT:InvestigationalNewDrugMember srt:MaximumMember us-gaap:PatentsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2020-10-01 2020-10-31 0001400271 CUBT:InvestigationalNewDrugMember srt:MinimumMember us-gaap:PatentsMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2020-10-01 2020-10-31 0001400271 CUBT:InvestigationalNewDrugMember srt:MaximumMember us-gaap:PatentsMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2020-10-01 2020-10-31 0001400271 CUBT:NationalInstituteOfHealthPatentLicenseOneMember 2020-10-01 2020-10-31 0001400271 us-gaap:RoyaltyMember CUBT:NationalInstituteOfHealthPatentLicenseTwoMember 2021-01-01 2021-01-31 0001400271 CUBT:RoyaltyOneMember CUBT:NationalInstituteOfHealthPatentLicenseTwoMember 2021-01-01 2021-01-31 0001400271 CUBT:RoyaltyOneMember CUBT:NationalInstituteOfHealthPatentLicenseTwoMember 2022-01-01 2022-06-30 0001400271 CUBT:WebsiteMember 2022-01-01 2022-06-30 0001400271 us-gaap:PatentsMember CUBT:IEMIncMember 2022-04-01 2022-04-30 0001400271 CUBT:InvestigationalNewDrugMember us-gaap:PatentsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2020-10-01 2020-10-31 0001400271 CUBT:InvestigationalNewDrugMember us-gaap:PatentsMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2020-10-01 2020-10-31 0001400271 CUBT:TwoNotesMember srt:OfficerMember 2021-06-30 0001400271 CUBT:ThirteenNotesMember 2021-01-01 2021-03-31 0001400271 CUBT:TwoNotesPayableMember 2021-03-31 0001400271 CUBT:TwoNotesPayableMember 2021-01-01 2021-03-31 0001400271 CUBT:TwoNotesPayableMember us-gaap:SeriesCPreferredStockMember 2021-01-01 2021-03-31 0001400271 CUBT:ThirteenNotesPayableMember 2020-12-31 0001400271 CUBT:ThirteenNotesPayableMember 2020-01-01 2020-12-31 0001400271 CUBT:ThirteenNotesPayableMember us-gaap:SeriesCPreferredStockMember 2020-01-01 2020-12-31 0001400271 CUBT:ThirteenNotesPayableMember 2021-03-31 0001400271 CUBT:ThirteenNotesPayableMember 2021-01-01 2021-03-31 0001400271 CUBT:PromissoryNoteExchangeMember 2022-04-01 2022-06-30 0001400271 CUBT:PromissoryNoteExchangeMember 2022-01-01 2022-06-30 0001400271 CUBT:PromissoryNoteExchangeMember 2022-06-30 0001400271 CUBT:DirectorsAndOfficersMember 2022-03-31 0001400271 CUBT:DirectorsAndOfficersMember 2022-06-30 0001400271 CUBT:TwoNotesPayableMember us-gaap:SeriesCPreferredStockMember 2021-03-31 0001400271 us-gaap:SeriesCPreferredStockMember 2021-01-01 2021-03-31 0001400271 us-gaap:ConvertibleNotesPayableMember 2013-04-30 0001400271 us-gaap:ConvertibleNotesPayableMember 2013-04-30 2013-04-30 0001400271 us-gaap:ConvertibleNotesPayableMember 2020-01-01 2020-12-31 0001400271 us-gaap:ConvertibleNotesPayableMember 2021-01-01 2021-12-31 0001400271 CUBT:TwelveMonthSeniorSecuredNoteMember 2022-03-31 0001400271 CUBT:TwelveMonthSeniorSecuredNoteMember 2022-03-01 2022-03-31 0001400271 CUBT:BeginningInSeptemberTwoThousandAndTwentyTwoMember 2022-01-01 2022-06-30 0001400271 CUBT:BeginningInSeptemberTwoThousandAndTwentyTwoMember 2022-06-30 0001400271 us-gaap:CommonStockMember 2020-03-01 2020-03-31 0001400271 us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-12-31 0001400271 us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-12-31 0001400271 us-gaap:SeriesCPreferredStockMember 2021-01-01 2021-12-31 0001400271 2021-10-01 2021-12-31 0001400271 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001400271 CUBT:MABTsCOVID19VaccineMember 2021-10-01 2021-12-31 0001400271 2021-07-01 2021-09-30 0001400271 2021-09-30 0001400271 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001400271 CUBT:AdvisoryBoardMember 2021-07-01 2021-09-30 0001400271 2021-12-01 2021-12-31 0001400271 us-gaap:SubsequentEventMember 2022-04-01 2022-04-30 0001400271 srt:ScenarioForecastMember 2022-08-01 2022-08-31 0001400271 CUBT:BoardOfDirectorsMember 2021-07-01 2021-09-30 0001400271 CUBT:AdvisoryBoardOneMember 2021-07-01 2021-09-30 0001400271 us-gaap:ConvertibleNotesPayableMember 2021-07-01 2021-09-30 0001400271 us-gaap:SeriesBPreferredStockMember 2021-09-30 0001400271 CUBT:AdvisoryBoardMember 2021-04-01 2021-06-30 0001400271 2021-08-01 2021-08-31 0001400271 srt:ScenarioForecastMember 2022-04-01 2022-04-30 0001400271 CUBT:EmployeeMember 2021-04-01 2021-06-30 0001400271 CUBT:EmployeesMember 2021-04-01 2021-06-30 0001400271 CUBT:EmployeeMember 2021-09-01 2021-09-30 0001400271 CUBT:EmployeeMember 2021-12-01 2021-12-31 0001400271 CUBT:EmployeeMember us-gaap:SubsequentEventMember 2022-03-01 2022-03-31 0001400271 CUBT:TwoEmployeesMember 2021-04-01 2021-06-30 0001400271 us-gaap:CommonStockMember CUBT:ExchangeForServicesMember 2021-01-01 2021-03-31 0001400271 us-gaap:CommonStockMember 2021-03-31 0001400271 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001400271 us-gaap:SeriesAPreferredStockMember 2021-03-31 0001400271 us-gaap:SeriesBPreferredStockMember 2021-03-31 0001400271 us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2021-03-31 0001400271 us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001400271 2021-01-01 2021-03-31 0001400271 us-gaap:WarrantMember 2021-01-01 2021-03-31 0001400271 2020-10-01 2020-12-31 0001400271 us-gaap:SeriesAPreferredStockMember 2020-10-01 2020-12-31 0001400271 us-gaap:SeriesCPreferredStockMember 2020-10-01 2020-12-31 0001400271 2020-04-01 2020-06-30 0001400271 2020-06-30 0001400271 2020-01-01 2020-03-31 0001400271 2020-03-31 0001400271 us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-06-30 0001400271 CUBT:SeriesAConvertiblePreferredStockMember us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001400271 us-gaap:SeriesBPreferredStockMember 2022-01-01 2022-06-30 0001400271 us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-03-31 0001400271 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2021-04-01 2021-06-30 0001400271 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2022-01-01 2022-03-31 0001400271 us-gaap:WarrantMember 2021-10-01 2021-12-31 0001400271 CUBT:MidAtlanticBiTheraputicsIncMember 2021-10-01 2021-12-31 0001400271 CUBT:AdvisoryBoardMember 2021-12-01 2021-12-31 0001400271 CUBT:AdvisoryBoardMember us-gaap:SubsequentEventMember 2022-04-01 2022-04-30 0001400271 srt:ScenarioForecastMember CUBT:AdvisoryBoardMember 2022-08-01 2022-08-31 0001400271 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001400271 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001400271 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001400271 CUBT:SeriesABCPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001400271 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001400271 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001400271 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001400271 CUBT:SeriesABCPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001400271 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001400271 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001400271 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001400271 CUBT:SeriesABCPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001400271 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001400271 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001400271 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001400271 CUBT:SeriesABCPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001400271 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001400271 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001400271 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001400271 CUBT:SeriesABCPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001400271 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-06-30 0001400271 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-06-30 0001400271 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-06-30 0001400271 CUBT:SeriesABCPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-06-30 0001400271 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-06-30 0001400271 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-06-30 0001400271 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-06-30 0001400271 CUBT:SeriesABCPreferredStockMember us-gaap:PreferredStockMember 2022-06-30 0001400271 us-gaap:WarrantMember 2021-12-31 0001400271 srt:MinimumMember 2021-12-31 0001400271 srt:MaximumMember 2021-12-31 0001400271 us-gaap:CommonStockMember 2021-09-30 0001400271 srt:MinimumMember 2021-09-30 0001400271 srt:MaximumMember 2021-09-30 0001400271 us-gaap:WarrantMember 2021-09-30 0001400271 us-gaap:WarrantMember 2021-07-01 2021-09-30 0001400271 srt:MinimumMember 2021-06-30 0001400271 CUBT:LegalServicesMember 2021-06-30 0001400271 CUBT:LegalServicesMember srt:MaximumMember 2021-06-30 0001400271 us-gaap:WarrantMember 2021-06-30 0001400271 srt:MaximumMember 2021-06-30 0001400271 2021-05-01 2021-05-31 0001400271 2021-09-01 2021-09-30 0001400271 us-gaap:SubsequentEventMember 2022-01-20 2022-01-20 0001400271 us-gaap:SubsequentEventMember 2022-05-01 2022-05-31 0001400271 2021-03-31 0001400271 us-gaap:WarrantMember 2021-03-31 0001400271 srt:MaximumMember 2021-03-31 0001400271 CUBT:WarrantsMember 2021-03-31 0001400271 srt:MinimumMember CUBT:WarrantsMember 2021-03-31 0001400271 srt:MaximumMember CUBT:WarrantsMember 2021-03-31 0001400271 srt:MinimumMember CUBT:WarrantsMember 2021-01-01 2021-03-31 0001400271 srt:MaximumMember CUBT:WarrantsMember 2021-01-01 2021-03-31 0001400271 CUBT:TwoPeoplesMember 2020-12-31 0001400271 us-gaap:WarrantMember 2020-12-31 0001400271 srt:MaximumMember CUBT:TwoPeoplesMember 2020-10-01 2020-12-31 0001400271 srt:MinimumMember CUBT:TwoPeoplesMember 2020-10-01 2020-12-31 0001400271 us-gaap:CommonStockMember 2022-03-31 0001400271 CUBT:ConvertibleSeniorSecuredNoteMember 2022-03-31 0001400271 srt:MinimumMember CUBT:WarrantsMember CUBT:BlackScholesMember 2021-03-31 0001400271 CUBT:BoardOfAdvisoryMember 2021-07-01 2021-09-30 0001400271 CUBT:BoardOfAdvisoryMember 2021-09-30 0001400271 CUBT:BoardOfAdvisoryMember us-gaap:SubsequentEventMember 2022-09-01 2022-09-30 0001400271 CUBT:ThreeEmployeesMember 2022-03-31 0001400271 CUBT:ThreeEmployeesMember 2022-01-01 2022-03-31 0001400271 CUBT:EmployeesMember 2022-01-01 2022-03-31 0001400271 CUBT:EmployeesMember 2022-03-31 0001400271 CUBT:EmployeesMember 2022-01-01 2022-06-30 0001400271 2022-01-01 2022-03-31 0001400271 2022-03-31 0001400271 us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember 2022-03-31 0001400271 us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember 2022-03-01 2022-03-31 0001400271 us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember 2022-09-01 2022-09-30 0001400271 us-gaap:SubsequentEventMember 2022-09-30 0001400271 us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember 2022-09-30 0001400271 us-gaap:SubsequentEventMember 2022-01-31 0001400271 CUBT:ThreeEmployeesMember us-gaap:StockOptionMember us-gaap:SubsequentEventMember 2022-01-31 0001400271 CUBT:ThreeEmployeesMember us-gaap:StockOptionMember us-gaap:SubsequentEventMember 2022-01-01 2022-01-31 0001400271 srt:MaximumMember CUBT:ConvertibleSeniorSecuredNotePayableAndWarrantsMember CUBT:LenderMember us-gaap:SubsequentEventMember 2022-08-31 0001400271 srt:MinimumMember CUBT:ConvertibleSeniorSecuredNotePayableAndWarrantsMember CUBT:LenderMember us-gaap:SubsequentEventMember 2022-08-31 0001400271 CUBT:ConvertibleSeniorSecuredNotePayableAndWarrantsMember CUBT:LenderMember us-gaap:SubsequentEventMember 2022-08-29 2022-08-31 0001400271 CUBT:ConvertibleSeniorSecuredNotePayableAndWarrantsMember CUBT:LenderMember us-gaap:SubsequentEventMember 2022-08-31 iso4217:USD shares iso4217:USD shares pure 0001400271 true Curative Biotechnology Inc S-1/A

P6M

P5Y

AMENDMENT NO. 6 FL 2836 26-1412177 1825 NW Corporate Blvd Suite 110 Boca Raton FL 33431 (561) 907-8990 Non-accelerated Filer true true false

670263

160607

25000

58642

1900859

70000

753905

2131466

6834

81515

114

79177

6720

2338

92975

1558550

140300

1651525

140300

2412150

2274104

726904

97830

128700

3431 7400

25415

405646

730335

664991

730335

664991

134109750

1564251

30000000

18043557

4566502

18043557

4566502

0.0001

200000000

81000

293000

0.0001

1100000000

570651636

333000327

57065

33300

10498221

3544658

-26917036

-8099627

-16361742

-4521640

2412150

2274104

4211355

4598302

779275

16958

32136

6744

5301

5014332

4635739

-5014332

-4635739

176672

34516

-149350

-326022

-34516

-5340354

-4670255

13477055

4440

-18817409

-4674695

-0.04 -0.01 500981957 326678469

322800327

34402750

32280

3304188

-3424932

-88435

1700000

170

36630

36800

8500000

850

105150

106000

54555

44135 44135 100000000 30000000

4440

-4670255

333000327

164402750

33300

3544658

-8099627

-4521640

333000327

164402750

33300

3544658

-8099627

-4521640

8715000

872

539264

540136

12500000

1250

1423750

1425000

9533

485487 485487

135836702

-134109750

13584

1550667

1564251

28266666 -212000 2826 -21 -2805 0

27520442

2752

1570248

1573000

10937499 1094 655156 656250 10500000 1050 523950 525000 375000 37 11213 11250 2000000 200 179800 180000

1000000

100

7300

7400

13477055

-5340354

570651636

30081000

57065

10498221

-26917036

-16361742

570651636

30081000

57065

10498221

-26917036

-16361742

-5340354

-4670255

6744

5301

2889567

4302978

2545 11495

122129

19121

-149350

16958

32136

25000

18294

592320

109131

-1604035

-190093

6834

14500

34300

-21334

-34300

1573000

525000

70000

92975

48083

50000 20000 110000 365000

48083

2135025

385000

509656

160607

509656

160607

670263

160607

10000

1425000 106000 656250

1564251

9533 54555 13477055 4440

198650

NOTE 1 - NATURE OF OPERATIONS Curative Biotechnology Inc. (f/k/a Connectyx Technologies Holdings Group, Inc.), (CUBT), is a Florida corporation, formed as a Nevada corporation on June 29, 1995, reincorporated in Florida on October 30, 2007, with a name change November 30, 2020, which conducts business from its headquarters in Boca Raton, Florida. Curative Biotechnology, Inc. is a development stage biomedical company that seeks to develop, in-license, sub-license and bring to market products in both the Pharmaceutical and Medical Device space. The Company focuses on products that are targeted at FDA-defined “Orphan Diseases” with patient populations under 200,000 in the United States. The company leverages management’s experience and business relationships with Life Science research institutions as well as Life Science industry members to acquire Life Science candidates that fit within the company’s business model. The company has established a scientific advisory board with a successful track record of bringing pharmaceuticals to market.

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES a) Basis of Presentation The accompanying financial statements have been prepared in accordance with Generally Accepted Accounting Principles (“GAAP”) in the United States of America (“U.S.”) as promulgated by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). b) Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. (c) Cash and equivalents The Company considers all highly liquid investments with maturity of three months or less when purchased to be cash equivalents. (d) Prepaid expenses From time to time, the Company may prepay expenses either through the transfer of cash, assets or the issuance of securities. Prepaid expenses are amortized over the period of benefit. (e) Property and equipment All property and equipment are recorded at cost and depreciated over their estimated useful lives, using the straight-line method. Upon sale or retirement, the cost and related accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in the results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred. (f) Intangible Assets The useful life of intangible assets is assessed as either finite or indefinite. Following the initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses, if any. Intangible assets with finite useful lives are carried at cost less accumulated amortization. Amortization is calculated using the straight line method over the estimated useful lives. Intangible assets with indefinite useful lives are not amortized, but are tested for impairment annually. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis. If impairment indicators are present, these assets are subject to an impairment review. Any loss resulting from impairment of intangible assets is expensed in the period the impairment is identified. <p id="xdx_842_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zjlDjWsjcZib" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">(g) Impairment of Long-Lived Assets A long-lived asset is tested for impairment whenever events or changes in circumstances indicate that its carrying value amount may not be recoverable. An impairment loss is recognized when the carrying amount of the asset exceeds the sum of the undiscounted cash flows resulting from its use and eventual disposition. The impairment loss is measured as the amount by which the carrying amount of the long-lived assets exceeds its fair value. Curative Biotechnology, Inc Notes to Financial Statements NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued (h) Financial Instruments and Fair Value Measurements ASC 825-10 “Financial Instruments”, allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments. ASC 825 also requires disclosures of the fair value of financial instruments. The carrying value of the Company’s current financial instruments, which include cash and cash equivalents, accounts payable and accrued liabilities approximates their fair values because of the short-term maturities of these instruments. FASB ASC 820 “Fair Value Measurement” clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. It also requires disclosure about how fair value is determined for assets and liabilities and establishes a hierarchy for which these assets and liabilities must be grouped, based on significant levels of inputs as follows: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability. Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement. (i) Related Party Transactions All transactions with related parties are in the normal course of operations and are measured at the exchange amount. (j) Revenue Recognition The Company adopted Accounting Standards Codification, (“ASC”), 606, “Revenue from Contracts with Customer” on January 1, 2018. This revenue recognition standard has a five step process: a) Determine whether a contract exists; b) Identify the performance obligations; c) Determine the transaction price; d) Allocate the transaction price; e) Recognize revenue when (or as) performance obligations are satisfied. The Company’s financial statements are prepared under the accrual method of accounting. Revenues will be recognized when pervasive evidence of an arrangement exists, services have been rendered (product delivered), the sales price is fixed or determinable, and collectability is reasonably assured. This occurs only when the product(s) is ordered and subsequently delivered. <p id="xdx_842_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z9o0osiwDhVg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">(k) Stock based compensation Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award. The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. Pursuant to ASC 505-50, for share-based payments to non-employees, compensation expense is determined at the “measurement date.” The expense is recognized over the service period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting date. Curative Biotechnology, Inc Notes to Financial Statements NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued (l) Income Taxes Provisions for income taxes are based on taxes payable or refundable for the current year and deferred taxes on temporary differences between the amount of taxable income and pretax financial income, and between the tax bases of assets and liabilities and their reported amounts in the financial statements. Deferred tax assets and liabilities are included in the consolidated financial statements at currently enacted income tax rates applicable to the period in which the deferred tax assets and liabilities are expected to be realized or settled as prescribed in FASB ASC 740. As changes in tax laws or rates are enacted, deferred tax assets and liabilities are adjusted through the provision for income taxes. Tax positions initially need to be recognized in the financial statements when it is more-likely-than-not the positions will be sustained upon examination by the tax authorities. (m) Net income (loss) per share Basic loss per share is computed by dividing the net income (loss) by the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the Company. Diluted loss per share is computed by dividing the loss available to stockholders by the weighted average number of shares outstanding for the period and dilutive potential shares outstanding unless consideration of such dilutive potential shares would result in anti-dilution. There were no dilutive common stock equivalents for the years ended December 31, 2021 and 2020. <p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zZ9muM27k8a8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">(n) Recent Accounting Pronouncements The Company has considered recent accounting pronouncements during the preparation of these financial statements.

a) Basis of Presentation The accompanying financial statements have been prepared in accordance with Generally Accepted Accounting Principles (“GAAP”) in the United States of America (“U.S.”) as promulgated by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”).

b) Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

(c) Cash and equivalents The Company considers all highly liquid investments with maturity of three months or less when purchased to be cash equivalents.

(d) Prepaid expenses From time to time, the Company may prepay expenses either through the transfer of cash, assets or the issuance of securities. Prepaid expenses are amortized over the period of benefit.

(e) Property and equipment All property and equipment are recorded at cost and depreciated over their estimated useful lives, using the straight-line method. Upon sale or retirement, the cost and related accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in the results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred.

(f) Intangible Assets The useful life of intangible assets is assessed as either finite or indefinite. Following the initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses, if any. Intangible assets with finite useful lives are carried at cost less accumulated amortization. Amortization is calculated using the straight line method over the estimated useful lives. Intangible assets with indefinite useful lives are not amortized, but are tested for impairment annually. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis. If impairment indicators are present, these assets are subject to an impairment review. Any loss resulting from impairment of intangible assets is expensed in the period the impairment is identified.

<p id="xdx_842_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zjlDjWsjcZib" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">(g) Impairment of Long-Lived Assets A long-lived asset is tested for impairment whenever events or changes in circumstances indicate that its carrying value amount may not be recoverable. An impairment loss is recognized when the carrying amount of the asset exceeds the sum of the undiscounted cash flows resulting from its use and eventual disposition. The impairment loss is measured as the amount by which the carrying amount of the long-lived assets exceeds its fair value.

(h) Financial Instruments and Fair Value Measurements ASC 825-10 “Financial Instruments”, allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments. ASC 825 also requires disclosures of the fair value of financial instruments. The carrying value of the Company’s current financial instruments, which include cash and cash equivalents, accounts payable and accrued liabilities approximates their fair values because of the short-term maturities of these instruments. FASB ASC 820 “Fair Value Measurement” clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. It also requires disclosure about how fair value is determined for assets and liabilities and establishes a hierarchy for which these assets and liabilities must be grouped, based on significant levels of inputs as follows: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability. Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

(i) Related Party Transactions All transactions with related parties are in the normal course of operations and are measured at the exchange amount.

(j) Revenue Recognition The Company adopted Accounting Standards Codification, (“ASC”), 606, “Revenue from Contracts with Customer” on January 1, 2018. This revenue recognition standard has a five step process: a) Determine whether a contract exists; b) Identify the performance obligations; c) Determine the transaction price; d) Allocate the transaction price; e) Recognize revenue when (or as) performance obligations are satisfied. The Company’s financial statements are prepared under the accrual method of accounting. Revenues will be recognized when pervasive evidence of an arrangement exists, services have been rendered (product delivered), the sales price is fixed or determinable, and collectability is reasonably assured. This occurs only when the product(s) is ordered and subsequently delivered.

<p id="xdx_842_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z9o0osiwDhVg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">(k) Stock based compensation Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award. The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. Pursuant to ASC 505-50, for share-based payments to non-employees, compensation expense is determined at the “measurement date.” The expense is recognized over the service period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting date.

(l) Income Taxes Provisions for income taxes are based on taxes payable or refundable for the current year and deferred taxes on temporary differences between the amount of taxable income and pretax financial income, and between the tax bases of assets and liabilities and their reported amounts in the financial statements. Deferred tax assets and liabilities are included in the consolidated financial statements at currently enacted income tax rates applicable to the period in which the deferred tax assets and liabilities are expected to be realized or settled as prescribed in FASB ASC 740. As changes in tax laws or rates are enacted, deferred tax assets and liabilities are adjusted through the provision for income taxes. Tax positions initially need to be recognized in the financial statements when it is more-likely-than-not the positions will be sustained upon examination by the tax authorities.

(m) Net income (loss) per share Basic loss per share is computed by dividing the net income (loss) by the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the Company. Diluted loss per share is computed by dividing the loss available to stockholders by the weighted average number of shares outstanding for the period and dilutive potential shares outstanding unless consideration of such dilutive potential shares would result in anti-dilution. There were no dilutive common stock equivalents for the years ended December 31, 2021 and 2020.

<p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zZ9muM27k8a8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">(n) Recent Accounting Pronouncements The Company has considered recent accounting pronouncements during the preparation of these financial statements.

<p id="xdx_805_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zaFUB6lkbwz6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">NOTE 3 - LIQUIDITY AND GOING CONCERN CONSIDERATIONS The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company’s financial position and operating results raise substantial doubt about the Company’s ability to continue as a going concern, as reflected by the net loss of approximately $5.3 million and accumulated deficit of approximately $26.9 million through December 31, 2021. The ability of the Company to continue as a going concern is dependent upon commencing operations, developing sales and obtaining additional capital and financing. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The Company is currently seeking additional capital to allow it to grow its operations

-5300000

-26900000

NOTE 4 - INTANGIBLE ASSETS During the 4th quarter 2021, the Company acquired the following intangible asset: (a) MABT Covid-19 license The Company entered into a licensing agreement with Mid-Atlantic BioTheraputics, Inc., (MABT), to license MABT’s COVID-19 vaccine which is composed of a recombinant S1 and S2 protein from SARS-CoV-2 plus an IMT504 adjuvant. The Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pid_c20211001__20211231__dei--LegalEntityAxis__custom--MidAtlanticBioTheraputicsIncMember_zU8ZXrxnE42j" title="Common stock issued to acquire license, shares">12,500,000 shares of common stock valued at $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_c20211001__20211231__dei--LegalEntityAxis__custom--MidAtlanticBioTheraputicsIncMember_zW7hh5D1i6Lh" title="Common stock issued to acquire license">1,425,000 to acquire this license. During the 4th quarter 2020, the Company acquired the following intangible assets: (b) Website In December 2020, the Company contracted with a third party to develop and produce a new website for the Company for a contract price of $22,500, one-half in cash and one-half in common stock of the Company. The Company is amortizing this cost over 3 years. This website was placed into service in March 2021. Amortization expense for the year ended December 31, 2021 was $6,250. In March 2020, the Company contracted with a third party to develop and produce a new website for the Company for a contract price of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20200301__20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteMember_zqpHprB5bFvc" title="Common stock issued for services, value">15,000, for which the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20200301__20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteMember_zdpXSGfi1OV6" title="Common stock issued for services, shares">1,500,000 shares of common stock. Curative Biotechnology, Inc Notes to Financial Statements NOTE 4 - INTANGIBLE ASSETS, continued (c) Patent rights option In October 2020, the Company entered into an agreement for the option to purchase certain exclusive license rights for US Patent No. 8,287,505 Ophthalmic Drop Dispensing Tip Assembly, issued October 16, 2012, from IEM, Inc., (IEM), the sole owner of this patent. The cost of this option was $<span id="xdx_901_ecustom--CostOfOption_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__dei--LegalEntityAxis__custom--IEMIncMember_zA2uGTu7tpbd" title="Cost of option">1,800. <span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetsIntentOrAbilityToRenewOrExtendArrangement_c20210901__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__dei--LegalEntityAxis__custom--IEMIncMember_zAzrmbokNJOf" title="Option extension description">The Company had until September 30, 2021, to advise IEM in writing that it wishes to exercise this Option Right and pay IEM $<span id="xdx_90C_eus-gaap--PaymentsToAcquireIntangibleAssets_c20210901__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__dei--LegalEntityAxis__custom--IEMIncMember_z9meE9wMq1gc" title="Payment for royalty free perpetual license">50,000 in exchange for an exclusive world-wide, royalty free perpetual license. In September 2021, the Company exercised the option to extend the deadline for notification in the contract with IEM, from September 30, 2020 to March 31, 2022, in exchange for the payment of $<span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend_c20210901__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__dei--LegalEntityAxis__custom--IEMIncMember_z8IYxU0uFJP9" title="Payment for extension">1,000. The Company is evaluating the Patent rights, potential products and markets under this Patent. (d) IMT504 Patent license In October 2020, the Company entered into a license agreement with MidAtlantic BioTheraputics, Inc., (MABT), to license the development of a pharmaceutical compound known as IMT504, as immununotherapy for late stage symptomatic rabies. The license is for worldwide use. There are certain conditions to the license, principally that the Company raise $<span id="xdx_90C_ecustom--ProceedsForLicenseDevelopment_pn5n6_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__dei--LegalEntityAxis__custom--MidAtlanticBioTheraputicsIncMember_zCHEGCMkkQO9" title="Proceeds for patent license development">6.5 million to fund the development. There is not a time limit on raising these funds unless the Company utilizes a public offering process, such as Regulation A. <span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zg1CisFo3E0f" title="License transaction description">The total cost for this license is <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pn6n6_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--ProductOrServiceAxis__custom--InvestigationalNewDrugMember_zJgPpqk1lnne" title="Common stock issuable for cost of license, shares">20 million shares of the Company’s common stock, issuable in three tranches - <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pn6n6_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--ProductOrServiceAxis__custom--InvestigationalNewDrugMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__srt--RangeAxis__srt--MinimumMember_z095ToTmzRnj">1- <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pn6n6_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--ProductOrServiceAxis__custom--InvestigationalNewDrugMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__srt--RangeAxis__srt--MaximumMember_zFVAlWzCa0E3">7 million shares upon execution of the license (which have been issued, valued at $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--ProductOrServiceAxis__custom--InvestigationalNewDrugMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_pp0p0">91,000), <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pn6n6_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--ProductOrServiceAxis__custom--InvestigationalNewDrugMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__srt--RangeAxis__srt--MinimumMember_ziWrj2C25ePk">2- <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pn5n6_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--ProductOrServiceAxis__custom--InvestigationalNewDrugMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__srt--RangeAxis__srt--MaximumMember_zkdIMcCIFSFd">6.5 million shares upon the submission of an Investigational New Drug (IND) to the FDA and <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pn6n6_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--ProductOrServiceAxis__custom--InvestigationalNewDrugMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__srt--RangeAxis__srt--MinimumMember_zzP3kDXR4z13">3- <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pn5n6_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--ProductOrServiceAxis__custom--InvestigationalNewDrugMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__srt--RangeAxis__srt--MaximumMember_zatayMyc5ube" title="Common stock issued to acquire license, shares">6.5 million shares upon the successful completion of the first rabies clinical trial of this IND. This license calls for royalties of 50% of the net profit, after reimbursement for development costs, of successfully marketed products utilizing IMT504. (e) National Institute of Health (NIH) Patent license #1 In October 2020, the Company entered into an exclusive 24 month evaluation license of Provisional Patent Application No. 62/199,707, filed July 31, 2015; PCT Application No. PCT/US2016/044777 filed July 29, 2016 and Patent No. 10,548,987 issued February 4, 2020. This license is for the evaluation of and development of an anti-CD56 antibody drug conjugate for the treatment of glioblastoma. Should the Company develop a marketable product, the Company is then required to negotiate a new license with appropriate royalties. This license calls for the payment of a non-creditable non-refundable license issue royalty of $<span id="xdx_906_eus-gaap--PaymentsForRoyalties_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NationalInstituteOfHealthPatentLicenseOneMember_znEIVeYxfnTe" title="Payment of non-refundable license issue royalty">10,000, paid ½ at issuance and ½ on the one year anniversary. (f) National Institute of Health (NIH) Patent license #2 In January 2021 the Company entered into an NIH exclusive 36 month worldwide license of Provisional Patent Application No. 62/899,899, filed September 13, 2019 and PCT Application No. PCT/US2020/050540 filed September 11, 2020. This license is for the development of ocular metformin formulation for the treatment of retinal degenerative diseases. This license requires two separate royalty streams of payments: First is a royalty equal to the unreimbursed patent expenses paid by NIH, with an initial amount of $<span id="xdx_90C_eus-gaap--RoyaltyExpense_c20210101__20210131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NationalInstituteOfHealthPatentLicenseTwoMember__srt--ProductOrServiceAxis__us-gaap--RoyaltyMember_ztrg8xPXPOEb" title="Patent expense initial amount payable">8,500 due within 30 days of execution of the license. At the first anniversary of the license NIH will supply a statement of additional unreimbursed patent expenses paid by NIH during the year, of which the Company is required to pay 50%, with the remaining balance due on the third anniversary. Curative Biotechnology, Inc Notes to Financial Statements NOTE 4 - INTANGIBLE ASSETS, continued (f) National Institute of Health (NIH) Patent license #2, continued Second is an ongoing royalty schedule: an initial royalty of $<span id="xdx_90E_eus-gaap--RoyaltyExpense_c20210101__20210131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NationalInstituteOfHealthPatentLicenseTwoMember__srt--ProductOrServiceAxis__custom--RoyaltyOneMember_pp0p0" title="Patent expense initial amount payable">5,000 upon execution of the license, and annually thereafter as the minimum royalty amount. <span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsIntentOrAbilityToRenewOrExtendArrangement_c20220101__20220630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NationalInstituteOfHealthPatentLicenseTwoMember__srt--ProductOrServiceAxis__custom--RoyaltyOneMember_z8e5ztx7teQ6" title="Option extension description">The license can be extended on the third anniversary to the remaining life of the licensed patent by the payment of a one-time non-refundable, non-creditable royalty of $<span id="xdx_90B_eus-gaap--PaymentsForRoyalties_c20210101__20210131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NationalInstituteOfHealthPatentLicenseTwoMember__srt--ProductOrServiceAxis__custom--RoyaltyOneMember_pp0p0" title="Payment of non-refundable license issue royalty">45,000. There are three benchmark royalties - $75,000 upon the initiation of the first Phase 2 Clinical Study; $300,000 upon the completion of Phase 3 Clinical Study and $600,000 upon the FDA approval of the first Licensed Product. Upon first commercial sale there is a royalty of $100,000 each for the United States, Canada, European Union and Asian region. Last is a 3.5% of net sales royalty. The patent rights and patent licenses are under development, therefore amortization of the costs has not commenced, as these patent rights and licenses have not been placed in service.

12500000

1425000

22500

P3Y

6250

15000

1500000

1800

The Company had until September 30, 2021, to advise IEM in writing that it wishes to exercise this Option Right and pay IEM $50,000 in exchange for an exclusive world-wide, royalty free perpetual license. In September 2021, the Company exercised the option to extend the deadline for notification in the contract with IEM, from September 30, 2020 to March 31, 2022, in exchange for the payment of $1,000

50000

1000

6500000

The total cost for this license is 20 million shares of the Company’s common stock, issuable in three tranches - 1- 7 million shares upon execution of the license (which have been issued, valued at $91,000), 2- 6.5 million shares upon the submission of an Investigational New Drug (IND) to the FDA and 3- 6.5 million shares upon the successful completion of the first rabies clinical trial of this IND. This license calls for royalties of 50% of the net profit, after reimbursement for development costs, of successfully marketed products utilizing IMT504.

20000000

1000000

7000000

91000

2000000

6500000

3000000

6500000

10000

8500

5000

The license can be extended on the third anniversary to the remaining life of the licensed patent by the payment of a one-time non-refundable, non-creditable royalty of $45,000. There are three benchmark royalties - $75,000 upon the initiation of the first Phase 2 Clinical Study; $300,000 upon the completion of Phase 3 Clinical Study and $600,000 upon the FDA approval of the first Licensed Product. Upon first commercial sale there is a royalty of $100,000 each for the United States, Canada, European Union and Asian region. Last is a 3.5% of net sales royalty.

45000

<p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zeLOttqbRsOd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">NOTE 5 - RELATED PARTY TRANSACTIONS From time to time the Company may enter into non-arm’s length transactions with related parties, however the Company exercises its best efforts to ensure that such transactions are valued on a basis comparable to a true arm’s length transaction. During 2020, one officer advanced $48,083 to the Company, carrying no stated interest rate nor maturity. This advance was repaid during 2020. During the second quarter of 2021, the remaining two notes from officers of the Company, totaling $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember__us-gaap--DebtInstrumentAxis__custom--TwoNotesMember_zPCruMcgRUC1" title="Principal amount">40,000 of principal and $<span id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember__us-gaap--DebtInstrumentAxis__custom--TwoNotesMember_zbR3sGkLsed5" title="Original issue discount">10,000 of OID, were repaid in cash.

48083

40000

10000

NOTE 6 - NOTES PAYABLE During the first quarter 2021, 13 of the 15 total notes were converted into <span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210101__20210331__us-gaap--DebtInstrumentAxis__custom--ThirteenNotesMember_zqVoI9knFXmi" title="Debt notes converted into shares of common stock">10,937,499 shares of common stock. In January 2021, the amounts receivable for notes payable were received. During the first quarter of 2021, the Company entered into two (2) notes payable with a face amount of $137,500, including <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20210331__us-gaap--DebtInstrumentAxis__custom--TwoNotesPayableMember_zzs25KOScFm4" title="Original issue discount, percentage">25% Original Issue Discount (OID), for a total amount of cash received of $110,000. The notes are identical and carry a maturity of six months from inception and a <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20210331__us-gaap--DebtInstrumentAxis__custom--TwoNotesPayableMember_ztPnQjq2rupb" title="Original issue discount, percentage">25% OID. The maturity is extendable at the Company’s option for up to three months with a 3% per month extension fee. In connection with the notes, the Company issued warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210331__us-gaap--DebtInstrumentAxis__custom--TwoNotesPayableMember_zClqOYkUhw5e" title="Purchase of common stock warrants">1,100,000 shares of common stock of the Company, which were recorded as a discount in the amount of $9,533, which is being amortized over the term of the notes. These notes are collateralized by Preferred C shares representing <span id="xdx_90A_ecustom--IssuedAndOutstandingSharesPercentage_pid_dp_c20210101__20210331__us-gaap--DebtInstrumentAxis__custom--TwoNotesPayableMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zhxBxqH2e1h9" title="Issued and outstanding common stock shares, percentage">9.24% of the issued and outstanding common stock shares. Two officers holding Preferred C shares have pledged the Preferred C shares as this collateral. During 2020, the Company issued thirteen (13) notes payable with a face amount of $568,750, including 25% OID, for a total amount of cash received of $455,000. The notes are identical and carry a six-month maturity. The maturity is extendable at the Company’s option for up to three months with a 3% per month extension fee. In connection with the notes, the Company issued warrants to purchase 4,550,000 shares of common stock of the Company, which were recorded as a discount in the amount of $54,555, which is being amortized over the term of the notes. These notes are collateralized by Preferred C shares representing <span id="xdx_90D_ecustom--IssuedAndOutstandingSharesPercentage_pid_dp_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--ThirteenNotesPayableMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zRrBD0wD2jTh">9.24% of the issued and outstanding common stock shares. Two officers holding Preferred C shares have pledged the Preferred C shares as this collateral. During the first quarter of 2021, 13 of the 15 note holders converted their notes into shares of common stock at the rate of $0.06 per share, for a total of 10,937,499 shares of common stock for a total of $656,250 convertible debt. Curative Biotechnology, Inc Notes to Financial Statements

10937499

137500

0.25

110000

P6M

0.25

The maturity is extendable at the Company’s option for up to three months with a 3% per month extension fee

1100000

9533

0.0924

568750

0.25

455000

The maturity is extendable at the Company’s option for up to three months with a 3% per month extension fee

4550000

54555

0.0924

0.06

10937499

656250

NOTE 7 - CONVERTIBLE NOTE PAYABLE CONVERTIBLE SENIOR SECURED NOTE PAYABLE In April 2013, the Company entered into a convertible note in the principal amount of $97,500, which carried a <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPercent_c20130430__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z3HEjLKLPcLe" title="Debt instrument interest rate">4% interest rate. This note was convertible at a conversion price equal to the lesser of <span id="xdx_904_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_c20130430__20130430__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zzLgphdAA0Ha" title="Debt conversion price percentage">90% of the previous 10 day closing price or $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20130430__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zCQoyGzNHcS5" title="Debt instrument conversion price per share">0.001 per share. The balance of the convertible note, including accrued interest, was $128,700 at December 31, 2020. During 2021, the note holder filed a lawsuit to enforce the conversion of this note, which was settled in August 2021, via the payment of $100,000 and the issuance of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zgmDiaoDxRBj" title="Issuance of common stock, shares">2,000,000 shares of common stock. (See Note 9)

97500

0.04

0.90

0.001

128700

100000

2000000

NOTE 8 - LIABILITY TO ISSUE COMMON STOCK In March 2020, the Company entered into an agreement to issue <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200301__20200331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5mItiXTMh4e" title="Issuance of common stock for services, shares">1,000,000 shares of the Company’s common stock in exchange for services valued at $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20200301__20200331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z47jhPchSuFj" title="Issuance of common stock for services, value">7,400. These shares were issued in June 2021.

1000000

7400

NOTE 9 – DEFICIENCY IN STOCKHOLDERS EQUITY At December 31, 2021 and 2020, the Company has 1,100,000,000 shares of par value $0.0001 common stock authorized and 570,651,636 and 333,000,327 issued and outstanding, respectively. At December 31, 2021 and 2020, the Company has 200,000,000 shares of $0.0001 par value preferred stock authorized. <p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zRA93aYVRLt8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The Company accounts for the Series A and Series C preferred stock in accordance with FASB Accounting Standards Codification (ASC) 480, as mezzanine equity due to Series A having a redemption provision and Series C being convertible into a variable number of common shares. SCHEDULE OF STOCKHOLDERS EQUITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesAPreferredStockMember_zWBeLL5y5Zhh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesBPreferredStockMember_zZO376Ay66Md" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesCPreferredStockMember_zgHXvtjHqlJc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--SeriesABCPreferredStockMember_zdUinOwMAqjg" style="border-bottom: Black 1.5pt solid; font-weight: bold">Par</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series A</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series B</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series C</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold">Par</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_434_c20200101__20201231_eus-gaap--StockholdersEquity_iS_zyHvZZdpiM64" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%">January 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zhWiWpzS2Uhc" style="width: 5%; text-align: right" title="Beginning balance">34,109,750</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">3,411</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zdmx8cdufeKd" style="width: 5%; text-align: right" title="Beginning balance">293,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">29</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zq2Q09ItaJAf" style="width: 5%; text-align: right" title="Beginning balance">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesABCPreferredStockMember_zBNFilPEUpuf" style="width: 5%; text-align: right" title="Beginning balance">34,402,750</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">3,440</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zReSXNvCARpi" style="vertical-align: bottom; background-color: White"> <td>Issuance of shares for services</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zlVcQ72bkkx9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Issuance of shares for services, shares">100,000,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zRLEljNlVKSa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Issuance of shares for services, shares">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zsoDTzr20bQa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Issuance of shares for services, shares">30,000,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesABCPreferredStockMember_zkE17OPTw7Qe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Issuance of shares for services, shares">130,000,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_43B_c20210101__20211231_eus-gaap--StockholdersEquity_iS_zprcfNO2KAR9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>December 31, 2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zQ21WRdZk6xb" style="text-align: right">134,109,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,411</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z5ntKi02BfS8" style="text-align: right">293,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zhdLrZ7WKYAi" style="text-align: right">30,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesABCPreferredStockMember_zlj1MqMEfurf" style="text-align: right">164,402,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,440</td><td style="text-align: left"> </td></tr> <tr id="xdx_430_c20210101__20211231_eus-gaap--StockholdersEquity_iS_ze9WxTlbUnV" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Beginning Balance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">134,109,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,411</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">293,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">164,402,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,440</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zUgzIvNM1N33" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Conversion to common shares</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zMCnczaEZOBb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversion to common shares, shares">(134,109,750</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,411</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zsUVaeBCR6Lk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversion to common shares, shares">(212,000</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zh6U7kfzypta" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversion to common shares, shares">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesABCPreferredStockMember_zJBCXuCShRcf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversion to common shares, shares">(134,321,750</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,432</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueOther_zeEAhKVpM2p4" style="display: none; vertical-align: bottom; background-color: White"> <td style="display: none; text-align: left">no transactions</td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right" title="Conversion to common shares, shares"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right" title="Conversion to common shares, shares"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right" title="Conversion to common shares, shares"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right" title="Conversion to common shares, shares"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodSharesOther_zf3rSjP531vi" style="display: none; vertical-align: bottom; background-color: White"> <td style="display: none; text-align: left">no transactions, shares</td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right" title="Conversion to common shares, shares"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right" title="Conversion to common shares, shares"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right" title="Conversion to common shares, shares"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right" title="Conversion to common shares, shares"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td></tr> <tr id="xdx_430_c20210101__20211231_eus-gaap--StockholdersEquity_iE_zxH6S5x9aa9k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>December 31, 2021</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zz0HYhONGKKh" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zqJ4I4c1bulc" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">81,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zejR31584Yth" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">30,000,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesABCPreferredStockMember_zjajCWfZUQd9" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">30,081,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,008</td><td style="text-align: left"> </td></tr> <tr id="xdx_431_c20210101__20211231_eus-gaap--StockholdersEquity_iE_zi5UQnSJiCGc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Ending Balance</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">81,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">30,000,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">30,081,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,008</td><td style="text-align: left"> </td></tr> </table> The preferred shares have the following respective rights and privileges: Series A Preferred carry 10 votes for each share of common stock that each Series A shares are convertible into at the record date; is convertible into common stock aggregating <span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPercent_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z6TXt1fbx8sk" title="Conversion price percentage">35% of the total issued and outstanding common shares at conversion date post conversion; are redeemable at the Company’s option for the greater of <span id="xdx_904_eus-gaap--DebtInstrumentRedemptionPricePercentage_pid_dp_uPercent_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zav3Sftm3ROi" title="Debt instrument, redemption price, percentage">45% of the total market value of the common shares or the calculation of the book value of the Company made by an independent audit firm or $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zIJmKyUuFEaj" title="Market value of common shares">5,000,000. Series B Preferred are convertible in common shares of common stock at a conversion price of $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zBuwlr7RH2ql" title="Debt instrument convertible conversion price">0.0075 per share; are redeemable at the Company’s option at a price of <span id="xdx_900_eus-gaap--DebtInstrumentRedemptionPricePercentage_dp_uPercent_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zjvOVpjziKkl" title="Redeemable price percentage">125% of the purchase price paid for the shares; carry one vote for each common share that the Series B is convertible into at the record date; are senior to all other securities in the event of a liquidation. Series C Preferred are convertible into common stock aggregating <span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPercent_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zzFwungggq44" title="Conversion price percentage">30% of the total issued and outstanding common shares at conversion date post conversion; carry ten votes for each common share that the Series C is convertible into at the record date. Curative Biotechnology, Inc Notes to Financial Statements NOTE 9 – DEFICIENCY IN STOCKHOLDERS EQUITY, continued During the fourth quarter 2021, the Company issued 13,159,331 shares of common stock and 25,915,437 warrants for the purchase of common stock in exchange for $523,000 in cash and $25,000 in deposit in transit. During the fourth quarter 2021, the Company issued 200,000 shares of common stock, valued at $21,960 for services. During the fourth quarter 2021, the Company issued 12,500,000 shares of common stock, valued at $1,425,000 for the license to MABT’s COVID-19 vaccine. During the third quarter 2021, the Company issued 4,361,111 shares of common stock and 4,236,111 warrants for the purchase of common stock in exchange for $425,000 in cash. During the third quarter 2021, the Company issued 250,000 shares of common stock, valued at $22,500, to an individual for services to be rendered as a member of the Company’s Advisory Board. These shares vest 60,000 immediately, 60,000 in December 2021, <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20220401__20220430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zvxLSj0PgfT1">60,000 in April 2022 and 70,000 in August 2022. During the third quarter 2021, the Company issued 300,000 shares of common stock, valued at $36,720, to an individual for services rendered as a member of the Company’s Board of Directors. During the third quarter 2021, the Company issued 250,000 shares of common stock, valued at $28,475, to an individual for services to be rendered as a member of the Company’s Advisory Board. These shares vested immediately. During the third quarter the Company issued 2,000,000 shares of common stock, valued at $180,000, to settle the lawsuit brought to enforce the convertible note. During the third quarter 2021, 9,000 shares of the Series B preferred stock was converted into <span id="xdx_903_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Perferred stock converted into common stock">1,200,000 shares of common stock. During the second quarter 2021, the Company issued 10,000,000 shares of common stock and 5,000,000 warrants for the purchase of common stock in exchange for $600,000 in cash. The warrants mature in May 2026, and carry an exercise price of $0.11 per share. During the second quarter 2021, the Company issued 1,000,000 shares of common stock to settle the liability to issue shares. During the second quarter 2021, the Company issued 250,000 shares of common stock to an individual for services to be rendered as a member of the Company’s Advisory Board. These shares vest 60,000 immediately, 60,000 in August 2021, 60,000 in December 2021 and <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20220401__20220430__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zNbwW0ZGuf31" title="Shares vested">70,000 in April 2022. During the second quarter 2021, the Company issued 840,000 shares of common stock to an employee for services to be rendered. These shares vest 210,000 immediately, 210,000 in September 2021, 210,000 in December 2021 and <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20220301__20220331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--EmployeeMember_zaolDWk1v28f">210,000 in March 2022. 840,000 of these shares to the two (2) individuals were issued and recorded as a prepaid expense to be amortized as they vest. During the first quarter 2021, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeForServicesMember_zGfpd8msWZHf">125,000 shares of common stock in exchange for services valued at $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeForServicesMember_zW4ZRvlrkEc2">5,575, or $0.0446 per share. During the first quarter 2021, the Company issued 375,000 shares of common stock to settle a payable in the amount of $11,250. During the first quarter 2021, all of the Series A preferred stock was converted into <span id="xdx_909_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_c20210331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Perferred stock converted into common stock">135,836,702 shares of common stock. During the first quarter 2021, 203,000 shares of the Series B preferred stock was converted into <span id="xdx_908_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_c20210331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Perferred stock converted into common stock">27,066,666 shares of common stock. During the first quarter of 2021, 13 of the 15 note holders converted their note receivable into shares of common stock at the rate of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_c20210331__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVzYmgFXgYzc" title="Shares issued price per share">0.06 per share, for a total of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zLRcF3m7VIG" title="Shares issued">10,937,499 shares of common stock for a total of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z0RZfBNO5clg">656,250 convertible debt. During the first quarter 2021, the Company issued 10,500,000 shares of common stock upon receipt of $525,000 in cash for the exercise of <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Warrants to purchase of common stock">10,500,000 warrants. During the first quarter 2021, the Company issued 6,500,000 shares of common stock for the exercise of 6,500,000 warrants in exchange for services valued at $325,000. During the 4th quarter 2020, the Company issued 1,700,000 shares of common stock in exchange for services valued at $36,800, or $0.0216 per share. During the 4th quarter 2020, the Company issued 8,500,000 shares of common stock to acquire intangible assets valued at $106,000, or $0.0125 per share. During the 4th quarter 2020, the Company issued 100,000,000 shares of Series A preferred stock in exchange for services valued at $1,560,840, or $0.0156 per share. During the 4th quarter 2020, the Company issued 30,000,000 shares of Series C preferred stock in exchange for services valued at $4,562,062, or $0.152 per share. 50% of the Series C shares vested upon issuance and the other 50% vest in May 2021. The Company recorded 50% of the compensation expense upon issuance and 50% as a prepaid expense which will be amortized over the remaining of the six month service period. During the 2nd quarter 2020, the Company issued 1,250,000 shares of common stock in exchange for services valued at $23,300, or $0.01864 per share. Curative Biotechnology, Inc Notes to Financial Statements NOTE 9 – DEFICIENCY IN STOCKHOLDERS EQUITY, continued During the 1st quarter 2020, the Company issued 1,500,000 shares of common stock in exchange for services valued at $15,000, or $0.01 per share. A deemed dividend for the Series C preferred stock is calculated and recorded as shares of common stock are issued. This is calculated as the increase in common shares that the Series C would receive upon conversion, as a result of the change in the number of common shares issued and outstanding during the period multiplied by the closing price of the common stock at the end of the period. The deemed dividend was 13,477,055 and $4,440 for the year ended December 31, 2021 and 202, respectively.

1100000000

0.0001

570651636

333000327

200000000

0.0001

<p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zRA93aYVRLt8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The Company accounts for the Series A and Series C preferred stock in accordance with FASB Accounting Standards Codification (ASC) 480, as mezzanine equity due to Series A having a redemption provision and Series C being convertible into a variable number of common shares. SCHEDULE OF STOCKHOLDERS EQUITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesAPreferredStockMember_zWBeLL5y5Zhh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesBPreferredStockMember_zZO376Ay66Md" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesCPreferredStockMember_zgHXvtjHqlJc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--SeriesABCPreferredStockMember_zdUinOwMAqjg" style="border-bottom: Black 1.5pt solid; font-weight: bold">Par</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series A</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series B</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series C</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold">Par</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_434_c20200101__20201231_eus-gaap--StockholdersEquity_iS_zyHvZZdpiM64" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%">January 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zhWiWpzS2Uhc" style="width: 5%; text-align: right" title="Beginning balance">34,109,750</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">3,411</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zdmx8cdufeKd" style="width: 5%; text-align: right" title="Beginning balance">293,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">29</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zq2Q09ItaJAf" style="width: 5%; text-align: right" title="Beginning balance">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesABCPreferredStockMember_zBNFilPEUpuf" style="width: 5%; text-align: right" title="Beginning balance">34,402,750</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">3,440</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zReSXNvCARpi" style="vertical-align: bottom; background-color: White"> <td>Issuance of shares for services</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zlVcQ72bkkx9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Issuance of shares for services, shares">100,000,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zRLEljNlVKSa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Issuance of shares for services, shares">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zsoDTzr20bQa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Issuance of shares for services, shares">30,000,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesABCPreferredStockMember_zkE17OPTw7Qe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Issuance of shares for services, shares">130,000,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_43B_c20210101__20211231_eus-gaap--StockholdersEquity_iS_zprcfNO2KAR9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>December 31, 2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zQ21WRdZk6xb" style="text-align: right">134,109,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,411</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z5ntKi02BfS8" style="text-align: right">293,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zhdLrZ7WKYAi" style="text-align: right">30,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesABCPreferredStockMember_zlj1MqMEfurf" style="text-align: right">164,402,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,440</td><td style="text-align: left"> </td></tr> <tr id="xdx_430_c20210101__20211231_eus-gaap--StockholdersEquity_iS_ze9WxTlbUnV" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Beginning Balance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">134,109,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,411</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">293,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">164,402,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,440</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zUgzIvNM1N33" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Conversion to common shares</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zMCnczaEZOBb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversion to common shares, shares">(134,109,750</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,411</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zsUVaeBCR6Lk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversion to common shares, shares">(212,000</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zh6U7kfzypta" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversion to common shares, shares">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesABCPreferredStockMember_zJBCXuCShRcf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversion to common shares, shares">(134,321,750</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,432</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueOther_zeEAhKVpM2p4" style="display: none; vertical-align: bottom; background-color: White"> <td style="display: none; text-align: left">no transactions</td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right" title="Conversion to common shares, shares"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right" title="Conversion to common shares, shares"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right" title="Conversion to common shares, shares"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right" title="Conversion to common shares, shares"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodSharesOther_zf3rSjP531vi" style="display: none; vertical-align: bottom; background-color: White"> <td style="display: none; text-align: left">no transactions, shares</td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right" title="Conversion to common shares, shares"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right" title="Conversion to common shares, shares"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right" title="Conversion to common shares, shares"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right" title="Conversion to common shares, shares"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td></tr> <tr id="xdx_430_c20210101__20211231_eus-gaap--StockholdersEquity_iE_zxH6S5x9aa9k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>December 31, 2021</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zz0HYhONGKKh" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zqJ4I4c1bulc" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">81,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zejR31584Yth" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">30,000,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesABCPreferredStockMember_zjajCWfZUQd9" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">30,081,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,008</td><td style="text-align: left"> </td></tr> <tr id="xdx_431_c20210101__20211231_eus-gaap--StockholdersEquity_iE_zi5UQnSJiCGc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Ending Balance</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">81,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">30,000,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">30,081,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,008</td><td style="text-align: left"> </td></tr> </table>

34109750

3411

293000

34402750

3440

100000000

10000

30000000

3000

130000000

13000

134109750

13411

293000

30000000

3000

164402750

16440

13411

3000

16440

-134109750

-13411

-212000

-21

-134321750

-13432

81000

30000000

3000

30081000

3008

3000

3008

Series A Preferred carry 10 votes for each share of common stock that each Series A shares are convertible into at the record date

0.35

0.45

5000000

0.0075

1.25

0.30

13159331

25915437

523000

25000

200000

21960

12500000

1425000

4361111

4236111

425000

250000

22500

60000

70000

300000

36720

250000

28475

2000000

180000

9000

1200000

10000000

5000000

600000

2026-05

0.11

1000000

250000

60000

70000

840000

210000

840000

125000

5575

0.0446

375000 11250

135836702

203000

27066666

0.06

10937499

656250

10500000

525000

10500000

6500000

325000

1700000

36800

0.0216

8500000

106000

0.0125

100000000

1560840

0.0156

30000000

4562062

0.152

50% of the Series C shares vested upon issuance and the other 50% vest in May 2021. The Company recorded 50% of the compensation expense upon issuance and 50% as a prepaid expense which will be amortized over the remaining of the six month service period.

1250000

23300

0.01864

1500000

15000

0.01

13477055 4440 NOTE 10 - WARRANTS During the fourth quarter 2021, the Company issued 403,225 warrants for the purchase of common stock of the Company in conjunction with the sale of 403,225 shares of common stock for cash. These warrants expire in December 2024 and have an exercise price of $0.11 per share. During the fourth quarter 2021, the Company issued 25,512,212 warrants for the purchase of common stock of the Company in conjunction with the sale of 12,756,106 shares of common stock for cash and subscription receivable. These warrants expire in December 2024 and have an exercise price of $0.09 and $0.15 per share. During the third quarter 2021, the Company issued 4,236,111 warrants for the purchase of common stock of the Company in conjunction with the sale of 4,361,111 shares of common stock for cash. These warrants expire in July and August 2026 and have an exercise price of $0.15 and $0.14 per share. During the third quarter 2021, the Company issued 1,000,000 warrants for the purchase of common stock of the Company in exchange for services as a member of the Board of Directors. These warrants expire in July 2024 and have an exercise price of $0.124 per share and have a cash-less exercise provision. These warrants were recorded at a total value of $34,382. During the second quarter 2021, the Company issued 5,000,000 warrants for the purchase of common stock of the Company in conjunction with the sale of 10,000,000 shares of common stock for cash. These warrants expire in May 2026 and have an exercise price of $0.11 per share. During the second quarter 2021, the Company issued 5,000,000 warrants for the purchase of common stock of the Company in exchange for services as a member of the Board of Directors. These warrants expire in June 2024 and have an exercise price of $0.20 per share. The warrants were recorded at a total value of $87,249. During the second quarter 2021, the Company issued 3,000,000 warrants for the purchase of common stock of the Company in exchange for legal services. These warrants expire in May 2026 and have an exercise price of $0.10 per share. The warrants were recorded at a total value of $155,717. During the second quarter 2021, the Company issued 1,000,000 warrants for the purchase of common stock of the Company in exchange for services. These warrants expire in May 2026 and have an exercise price of $0.10 per share. The warrants were recorded at a total value of $51,906 and vest <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20220120__20220120__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBfya8SfGHn3" title="Shares vested"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20220501__20220531__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNF0wURIZpZ9" title="Shares vested">250,000 shares on May 20, 2021 and September 20, 2021, January 20, 2022 and May 20, 2022. During the first quarter 2021, the Company issued 10,500,000 shares of common stock upon receipt of $525,000 in cash for the exercise of 10,500,000 warrants. During the first quarter 2021, the Company issued 6,500,000 shares of common stock in exchange for services valued at $325,000 for the exercise of 6,500,000 warrants. In the first quarter 2021, the Company issued 1,100,000 warrants for the purchase of common stock of the Company in conjunction with the short-term debt at the rate of 10 warrants for each $1 loaned. These warrants carry an expiration of thirty-six months from issuance; an exercise price of $0.05 per share and are exercisable immediately. The warrants were recorded at a total value of $9,533. In the first quarter 2021, the Company issued 5,000,000 warrants for services. These warrants carry an expiration of 60 months from issuance and an exercise price of $0.05 per share. The warrants were recorded at a total value of $40,600. The method utilized to value the warrants was the Black-Scholes model with the following assumption ranges: Expected life - three or five years; stock price between $0.04 and $0.10; volatility between <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_zcslsSnTdqq" title="Expected volatility rate">60.51 and <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_zXW87ZYpuSS6" title="Expected volatility rate">31.56; exercise price between $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20210331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_zUqQAvgFrOfe">0.05 and $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20210331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_zIa4rxixov4f">0.2 and bond equivalent yield rate between <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_z1Sx4Shz5Vac">0.09% and <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_zhYzpisC4nRd">0.83%. Curative Biotechnology, Inc Notes to Financial Statements NOTE 10 - WARRANTS, continued During the 4th quarter 2020, the Company issued 4,550,000 warrants for the purchase of common stock of the Company in conjunction with the issuance of short-term debt at the rate of 10 warrants for each $1 loaned. These warrants carry an expiration of thirty-six months from issuance; an exercise price of $0.05 per share and are exercisable immediately. These warrants were valued at $54,555, and are being amortized to the maturity of the related debt. During the 4th quarter 2020, the Company issued 6,750,000 warrants to two people for services. These warrants carry an expiration of 60 months from issuance and an exercise price of $0.05 per share. These warrants were valued at $44,135, and are being amortized over the service period. The method utilized to value the warrants was the Black-Scholes model with the following assumption ranges: Expected life three years; stock price $0.03; volatility between <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20201001__20201231__srt--TitleOfIndividualAxis__custom--TwoPeoplesMember__srt--RangeAxis__srt--MaximumMember_zqYtE69uLmkb">109.96 and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20201001__20201231__srt--TitleOfIndividualAxis__custom--TwoPeoplesMember__srt--RangeAxis__srt--MinimumMember_zCwkPgVoKzsi" title="Expected volatility rate">30.22; exercise price $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20201231__srt--TitleOfIndividualAxis__custom--TwoPeoplesMember_zupAKHafcMf2" title="Exercise price">0.05 and bond equivalent yield rate between <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20201001__20201231__srt--TitleOfIndividualAxis__custom--TwoPeoplesMember__srt--RangeAxis__srt--MinimumMember_zlMBBI1mh95d" title="Expected dividend rate">0.08% and <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20201001__20201231__srt--TitleOfIndividualAxis__custom--TwoPeoplesMember__srt--RangeAxis__srt--MaximumMember_zgifNGPH4Lvl" title="Expected dividend rate">0.11%.

403225

2024-12

0.11

25512212

12756106

2024-12

0.09

0.15

4236111

4361111

0.15

0.14

1000000

2024-07

0.124

34382

5000000

10000000

2026-05

0.11

5000000

0.20

87249

3000000

0.10

155717

1000000

0.10

51906

250000

10500000

525000

10500000

6500000

325000

6500000

1100000

0.05

9533

5000000

0.05

40600

P5Y

0.04

0.10

0.6051

0.3156

0.05

0.2

0.0009

0.0083

4550000

the Company in conjunction with the issuance of short-term debt at the rate of 10 warrants for each $1 loaned

0.05

54555

6750000

0.05

44135

P3Y

0.03

1.0996

0.3022

0.05

0.0008

0.0011

<p id="xdx_806_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z8lt74XzN39" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">NOTE 11 - OPTIONS In the third quarter of 2021, the Company issued options in conjunction with an agreement for Board of Advisor services and the evaluation of certain potential intangible asset acquisitions. These options call for an undivided 1% of the fully diluted issued and outstanding shares upon exercise. These options amounted to 8,081,037 shares at issuance date. These option s contain a single recalculation upon the completion of a reverse split of the existing common stock and the Company raising a minimum of $5 million in an offering. These options carry an exercise price of $0.11 per share and expire in September 2031. These options were valued at $436,908 and vest 50% upon issuance and <span id="xdx_900_ecustom--OptionsVestedPercentage_pid_dp_uPercent_c20220901__20220930__srt--TitleOfIndividualAxis__custom--BoardOfAdvisoryMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zO9awpCYWAo6">50% in September 2022. The method utilized to value the options was the Black-Scholes model with the following assumption ranges: Expected life - ten years; stock price $0.114; volatility 35.13; exercise price $0.11 and bond equivalent yield rate 1.47%.

0.01

8081037

5000000

0.11

436908

0.50 0.50

P10Y

0.114

0.3513

0.11

0.0147

NOTE 11 - EQUITY INCENTIVE PLAN During the quarter ended March 31, 2022, a total of 1,000,000 shares of common stock and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20220331__srt--TitleOfIndividualAxis__custom--EmployeesMember_zwR2LOgrYWWl" title="Number of options, Granted">7,456,500 options at a weighted-average exercise price of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20220331__srt--TitleOfIndividualAxis__custom--EmployeesMember_zuoR5PJopz1d" title="Weighted Average Exercise Price, Granted">0.0518 per share were granted to employees exercisable for a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dc_c20220101__20220331__srt--TitleOfIndividualAxis__custom--EmployeesMember_z9iZtoqoiq67" title="Expected term">five years with immediate vesting. The weighted-average fair value attributable to options granted in 2022 was $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20220331__srt--TitleOfIndividualAxis__custom--EmployeesMember_z0orJxpglDz1" title="Weighted-average grant date fair value">0.0208. <p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zlQboAyj8SG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify">Assumptions used in the pricing model for the quarter ended March 31, 2022, are as provided below. SCHEDULE OF FAIR VALUE OF STOCK OPTION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; border-collapse: collapse; width: 60%; margin-left: 1in"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none; width: 80%; text-align: left">Risk-free interest rate</td><td style="display: none; width: 2%"> </td> <td style="display: none; width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220101__20220331_zpQpMVYdzjKl" style="display: none; width: 16%; text-align: right" title="Risk-free interest rate">1.55</td><td style="display: none; width: 1%; text-align: left">%</td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="display: none">Exercise price</td><td style="display: none"> </td> <td style="display: none; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20220331_zedIt84xgxn6" style="display: none; text-align: right" title="Exercise price">0.0518</td><td style="display: none; text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none; text-align: left">Expected life</td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c20220101__20220331_zeQMU8D8wms6" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Expected life">5 years</td><td style="display: none; text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="display: none; text-align: left">Expected volatility</td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220101__20220331_zHA6FWeH41x7" style="display: none; text-align: right" title="Expected volatility">44.12</td><td style="display: none; text-align: left">%</td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none; text-align: left">Expected dividends</td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_c20220101__20220331_zDPaUr30DFc8" style="display: none; text-align: right" title="Expected dividends">-</td><td style="display: none; text-align: left"> </td></tr> </table> A summary of the Company’s stock option plan and changes during the quarter ended March 31, 2022, is as follows: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">Number of options</td><td style="display: none; font-weight: bold"> </td><td style="display: none; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="display: none; font-weight: bold"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none; text-align: left">Balance - beginning of the year</td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20220331_zgaqcTSzZbr3" style="display: none; text-align: right" title="Number of options, Beginning balance">-</td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220331_zjgFqFfIMGC" style="display: none; text-align: right" title="Weighted Average Exercise Price, Beginning Balance">-</td><td style="display: none; text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="display: none; width: 56%">Granted</td><td style="display: none; width: 2%"> </td> <td style="display: none; width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20220331_zlLW19ClZGHb" style="display: none; width: 18%; text-align: right" title="Number of options, Granted">7,456,500</td><td style="display: none; width: 1%; text-align: left"> </td><td style="display: none; width: 2%"> </td> <td style="display: none; width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20220331_zW2iZW2Mk0a" style="display: none; width: 18%; text-align: right" title="Weighted Average Exercise Price, Granted">0.0518</td><td style="display: none; width: 1%; text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none">Exercised</td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20220331_z6OvFzjpMvZa" style="display: none; text-align: right" title="Number of options,Exercised">-</td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20220331_zChA5OHAAtpa" style="display: none; text-align: right" title="Weighted Average Exercise Price,Exercised">-</td><td style="display: none; text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="display: none; padding-bottom: 1.5pt">Cancelled</td><td style="display: none; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; display: none; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20220101__20220331_zkbb9CpPEsA7" style="border-bottom: Black 1.5pt solid; display: none; text-align: right" title="Number of options, Cancelled">-</td><td style="display: none; padding-bottom: 1.5pt; text-align: left"> </td><td style="display: none; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; display: none; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20220331_ziv6a780tev" style="border-bottom: Black 1.5pt solid; display: none; text-align: right" title="Weighted Average Exercise Price, Cancelled">-</td><td style="display: none; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none; padding-bottom: 2.5pt">Balance - end of period</td><td style="display: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; display: none; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20220331_zn1yeTq3uGH7" style="border-bottom: Black 2.5pt double; display: none; text-align: right" title="Number of options, Ending Balance">7,456,500</td><td style="display: none; padding-bottom: 2.5pt; text-align: left"> </td><td style="display: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20220331_zpu70pAS6yCf" style="border-bottom: Black 2.5pt double; display: none; text-align: right" title="Weighted Average Exercise Price, Ending Balance">0.0518</td><td style="display: none; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> .

1000000

7456500

0.0518

P5Y

0.0208

<p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zlQboAyj8SG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify">Assumptions used in the pricing model for the quarter ended March 31, 2022, are as provided below. SCHEDULE OF FAIR VALUE OF STOCK OPTION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; border-collapse: collapse; width: 60%; margin-left: 1in"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none; width: 80%; text-align: left">Risk-free interest rate</td><td style="display: none; width: 2%"> </td> <td style="display: none; width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220101__20220331_zpQpMVYdzjKl" style="display: none; width: 16%; text-align: right" title="Risk-free interest rate">1.55</td><td style="display: none; width: 1%; text-align: left">%</td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="display: none">Exercise price</td><td style="display: none"> </td> <td style="display: none; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20220331_zedIt84xgxn6" style="display: none; text-align: right" title="Exercise price">0.0518</td><td style="display: none; text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none; text-align: left">Expected life</td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c20220101__20220331_zeQMU8D8wms6" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Expected life">5 years</td><td style="display: none; text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="display: none; text-align: left">Expected volatility</td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220101__20220331_zHA6FWeH41x7" style="display: none; text-align: right" title="Expected volatility">44.12</td><td style="display: none; text-align: left">%</td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none; text-align: left">Expected dividends</td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_c20220101__20220331_zDPaUr30DFc8" style="display: none; text-align: right" title="Expected dividends">-</td><td style="display: none; text-align: left"> </td></tr> </table>

0.0155

0.0518

P5Y

0.4412

A summary of the Company’s stock option plan and changes during the quarter ended March 31, 2022, is as follows: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">Number of options</td><td style="display: none; font-weight: bold"> </td><td style="display: none; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="display: none; font-weight: bold"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none; text-align: left">Balance - beginning of the year</td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20220331_zgaqcTSzZbr3" style="display: none; text-align: right" title="Number of options, Beginning balance">-</td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220331_zjgFqFfIMGC" style="display: none; text-align: right" title="Weighted Average Exercise Price, Beginning Balance">-</td><td style="display: none; text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="display: none; width: 56%">Granted</td><td style="display: none; width: 2%"> </td> <td style="display: none; width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20220331_zlLW19ClZGHb" style="display: none; width: 18%; text-align: right" title="Number of options, Granted">7,456,500</td><td style="display: none; width: 1%; text-align: left"> </td><td style="display: none; width: 2%"> </td> <td style="display: none; width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20220331_zW2iZW2Mk0a" style="display: none; width: 18%; text-align: right" title="Weighted Average Exercise Price, Granted">0.0518</td><td style="display: none; width: 1%; text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none">Exercised</td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20220331_z6OvFzjpMvZa" style="display: none; text-align: right" title="Number of options,Exercised">-</td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20220331_zChA5OHAAtpa" style="display: none; text-align: right" title="Weighted Average Exercise Price,Exercised">-</td><td style="display: none; text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="display: none; padding-bottom: 1.5pt">Cancelled</td><td style="display: none; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; display: none; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20220101__20220331_zkbb9CpPEsA7" style="border-bottom: Black 1.5pt solid; display: none; text-align: right" title="Number of options, Cancelled">-</td><td style="display: none; padding-bottom: 1.5pt; text-align: left"> </td><td style="display: none; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; display: none; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20220331_ziv6a780tev" style="border-bottom: Black 1.5pt solid; display: none; text-align: right" title="Weighted Average Exercise Price, Cancelled">-</td><td style="display: none; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none; padding-bottom: 2.5pt">Balance - end of period</td><td style="display: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; display: none; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20220331_zn1yeTq3uGH7" style="border-bottom: Black 2.5pt double; display: none; text-align: right" title="Number of options, Ending Balance">7,456,500</td><td style="display: none; padding-bottom: 2.5pt; text-align: left"> </td><td style="display: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20220331_zpu70pAS6yCf" style="border-bottom: Black 2.5pt double; display: none; text-align: right" title="Weighted Average Exercise Price, Ending Balance">0.0518</td><td style="display: none; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

7456500

0.0518

7456500

0.0518

NOTE 12 - FINANCIAL INSTRUMENTS (a) Liquidity Risk Liquidity risk is the risk that the Company will not be able to meet its obligations associated with financial liabilities. The Company relies on cash flows generated from operations, as well as injections of capital through the issuance of the Company’s capital stock to settle its liabilities when they become due. (b) Interest Rate Risk The Company is not exposed to significant interest rate risk due to the short-term maturity of its monetary current assets and current liabilities.

<p id="xdx_801_ecustom--GeneralAndAdmininstrativeDisclosureTextBlock_z5ur8jY7y41c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">NOTE 13 - GENERAL AND ADMINISTRATIVE EXPENSES <p id="xdx_89E_ecustom--SummaryOfGeneralAndAdministrativeExpenseTableTextBlock_zS6Qpe11VGk7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_494_20210101__20211231_zOHKiRAPMFcb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20200101__20201231_zhxQ0bltnSL8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--SalariesAndWages_maGAAEzKSx_zA1Wl81KdyAb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Salaries</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,016,881</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">143,065</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ShareBasedCompensation_maGAAEzKSx_zXUnUcjuw8ll" style="vertical-align: bottom; background-color: White"> <td>Share based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,889,567</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,302,978</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--ProfessionalFee_maGAAEzKSx_zMVKjr0fX8N3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">225,384</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">117,860</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherExpenses_maGAAEzKSx_zgrjl5EJbekj" style="vertical-align: bottom; background-color: White"> <td>Other</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">79,523</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">34,399</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_iT_mtGAAEzKSx_zIzw5dbODXjk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total general and administrative expenses</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,211,355</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,598,302</td><td style="text-align: left"> </td></tr> </table> Curative Biotechnology, Inc Notes to Financial Statements <p id="xdx_89E_ecustom--SummaryOfGeneralAndAdministrativeExpenseTableTextBlock_zS6Qpe11VGk7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_494_20210101__20211231_zOHKiRAPMFcb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20200101__20201231_zhxQ0bltnSL8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--SalariesAndWages_maGAAEzKSx_zA1Wl81KdyAb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Salaries</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,016,881</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">143,065</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ShareBasedCompensation_maGAAEzKSx_zXUnUcjuw8ll" style="vertical-align: bottom; background-color: White"> <td>Share based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,889,567</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,302,978</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--ProfessionalFee_maGAAEzKSx_zMVKjr0fX8N3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">225,384</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">117,860</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherExpenses_maGAAEzKSx_zgrjl5EJbekj" style="vertical-align: bottom; background-color: White"> <td>Other</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">79,523</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">34,399</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_iT_mtGAAEzKSx_zIzw5dbODXjk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total general and administrative expenses</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,211,355</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,598,302</td><td style="text-align: left"> </td></tr> </table> Curative Biotechnology, Inc Notes to Financial Statements

1016881

143065

2889567

4302978

225384 117860

79523

34399

4211355

4598302

NOTE 14 - IMPAIRMENT OF LONG-LIVED ASSETS NOTE 12 - IMPAIRMENT OF LONG LIVED ASSETS In the fourth quarter the Company determined that its fixed assets were obsolete and wrote off the undepreciated balance of $1,958. In March 2021, when the Company’s new website was placed in service, the remaining unamortized cost of the Company’s old website was written off, for a total of $15,000. During the 4th quarter 2020, the Company elected to abandon certain intangible assets it had been attempting to commercialize under previous management. As such the Company recorded a $34,516 impairment charge.

1958

15000

34516

NOTE 15 - INCOME TAXES The Company recognizes deferred tax assets and liabilities for the tax effects of differences between the financial statements and tax basis of assets and liabilities. A valuation allowance is established to reduce the deferred tax assets if it is more likely than not that a deferred tax asset will not be realized. The components of income tax provision (benefit) related to continuing operations are as follows at December 31: SCHEDULE OF COMPONENTS OF INCOME TAX EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 11pt; text-align: center"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_494_20210101__20211231_zu8iZ72kanI9" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_493_20200101__20201231_zrC8dXjJoIJ7" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--CurrentFederalTaxExpenseBenefit_maITEBzXHG_zjbcaDfzn7Bl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 62%">Current</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maITEBzXHG_zC4frHbFsTZf" style="vertical-align: bottom; background-color: White"> <td>Deferred</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzXHG_zW8sBDduX6U8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total tax provisions</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> </table> The following is a reconciliation of the effective income tax rate with the statutory income tax rate at December 31: SCHEDULE OF EFFECTIVE RECONCILIATION INCOME TAX RATE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_491_20210101__20211231_zYeb1v2aCWV7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_498_20200101__20201231_zMbCQfaKgnn7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_zNvl4MylXdK" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">U.S. Federal statutory income tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">(21</td><td style="width: 1%; text-align: left">)%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">(21</td><td style="width: 1%; text-align: left">)%</td></tr> <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_pid_dpi_z4NQTvW0X9mb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income tax, net of federal benefit</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4.5</td><td style="text-align: left">)%</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4.5</td><td style="text-align: left">)%</td></tr> <tr id="xdx_400_ecustom--EffectiveIncomeTaxRateReconciliationValuationAllowance_pid_dp_zpGHF2B1bcA4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Valuation allowance</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25.5</td><td style="text-align: left">%</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25.5</td><td style="text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_zoPZTDIqaN9g" style="vertical-align: bottom; background-color: White"> <td>Total</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="text-align: left">%</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_896_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zjLeAS1XTQ81" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The net deferred tax assets and liabilities included in the financial statements consist of the following amounts at December 31: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_491_20211231_zfTVESBk0Sc7" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td> </td><td> </td> <td colspan="2" id="xdx_49E_20201231_zfMYWn4rwKsc" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_zvK2UG5qrjnj" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Net operating loss carry forwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,337,957</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">831,988</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_zH6ZW68wfcp7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,600,548</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">958,197</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_iNI_di_ziJ0velN4byg" style="vertical-align: bottom; background-color: White"> <td>Other</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,061</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iTI_maDTANzW1K_zcVd1H9AaN01" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,938,505</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,780,124</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deferred tax liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzW1K_zVpYcy9KTV3d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: valuation allowance</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,938,505</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,780,124</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzW1K_zNI7bQjchAM9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net deferred tax assets</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td></tr> </table> Curative Biotechnology, Inc Notes to Financial Statements NOTE 15 - INCOME TAXES, continued The change in valuation allowance was ($1,158,381) and ($1,021,331) for the years ended December 31, 2021 and 2020, respectively. We have recorded a 100% valuation allowance related to the deferred tax asset for the income from operations. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which temporary differences become deductible. In accordance with the provisions of ASC 740: Income Taxes, we record a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. At December 31, 2021 and 2020, we have no liabilities for uncertain tax positions. We continually evaluate expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings.

The components of income tax provision (benefit) related to continuing operations are as follows at December 31: SCHEDULE OF COMPONENTS OF INCOME TAX EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 11pt; text-align: center"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_494_20210101__20211231_zu8iZ72kanI9" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_493_20200101__20201231_zrC8dXjJoIJ7" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--CurrentFederalTaxExpenseBenefit_maITEBzXHG_zjbcaDfzn7Bl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 62%">Current</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maITEBzXHG_zC4frHbFsTZf" style="vertical-align: bottom; background-color: White"> <td>Deferred</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzXHG_zW8sBDduX6U8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total tax provisions</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> </table>

The following is a reconciliation of the effective income tax rate with the statutory income tax rate at December 31: SCHEDULE OF EFFECTIVE RECONCILIATION INCOME TAX RATE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_491_20210101__20211231_zYeb1v2aCWV7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_498_20200101__20201231_zMbCQfaKgnn7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_zNvl4MylXdK" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">U.S. Federal statutory income tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">(21</td><td style="width: 1%; text-align: left">)%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">(21</td><td style="width: 1%; text-align: left">)%</td></tr> <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_pid_dpi_z4NQTvW0X9mb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income tax, net of federal benefit</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4.5</td><td style="text-align: left">)%</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4.5</td><td style="text-align: left">)%</td></tr> <tr id="xdx_400_ecustom--EffectiveIncomeTaxRateReconciliationValuationAllowance_pid_dp_zpGHF2B1bcA4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Valuation allowance</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25.5</td><td style="text-align: left">%</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25.5</td><td style="text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_zoPZTDIqaN9g" style="vertical-align: bottom; background-color: White"> <td>Total</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="text-align: left">%</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="text-align: left">%</td></tr> </table>

0.21

0.045

0.255 0.255

0.000

<p id="xdx_896_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zjLeAS1XTQ81" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The net deferred tax assets and liabilities included in the financial statements consist of the following amounts at December 31: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_491_20211231_zfTVESBk0Sc7" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td> </td><td> </td> <td colspan="2" id="xdx_49E_20201231_zfMYWn4rwKsc" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_zvK2UG5qrjnj" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Net operating loss carry forwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,337,957</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">831,988</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_zH6ZW68wfcp7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,600,548</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">958,197</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_iNI_di_ziJ0velN4byg" style="vertical-align: bottom; background-color: White"> <td>Other</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,061</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iTI_maDTANzW1K_zcVd1H9AaN01" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,938,505</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,780,124</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deferred tax liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzW1K_zVpYcy9KTV3d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: valuation allowance</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,938,505</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,780,124</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzW1K_zNI7bQjchAM9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net deferred tax assets</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td></tr> </table>

1337957

831988

1600548

958197

10061

2938505

1780124

2938505

1780124

1158381

1021331

NOTE 16 - COMMITMENTS AND CONTINGENCIES (a) Other The Company is subject to asserted claims and liabilities that arise in the ordinary course of business. The Company maintains insurance policies to mitigate potential losses from these actions. In the opinion of management, the amount of the ultimate liability with respect to those actions will not materially affect the Company’s financial position or results of operations.

NOTE 17 - CONCENTRATIONS OF CREDIT RISK (a) Cash The Company maintains its cash in bank deposit accounts, which may, at times, may exceed federally insured limits. The Company had $416,178 and no cash balance in excess of FDIC insured limits at December 31, 2021 and 2020.

416178

<p id="xdx_80E_eus-gaap--UnusualOrInfrequentItemsDisclosureTextBlock_zZSWSv9dH3X7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">NOTE 18 - COVID-19 PANDEMIC AND VARIANTS The full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial condition, will depend on future developments that are uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements, and although there is currently no major impact, there may be changes to those estimates in future periods.

NOTE 19 - SUBSEQUENT EVENTS (a) Intangible Assets In March 2022, the Company entered into a Cooperative Research and Development Agreement, (CRADA) with the National Institute of Health, (NIH). This is the next step in the process to commercialize NIH Patent License #2. The CRADA is for the clinical evaluation of the Company’s proprietary ocular metformin formulation. The National Eye Institute, (NEI), will conduct clinical studies under NIH protocols and the Company will provide the proprietary drug for the clinical studies. The terms of the CRADA are confidential. (b) Senior Secured Note In March 2022, the Company issued a 12 month Senior Secured Note with a face amount of $1,142,857, with a stated <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20220331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember_zME49qMt6mnd">12.5% original issue discount (OID). <span id="xdx_90B_eus-gaap--DebtInstrumentPaymentTerms_c20220301__20220331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember_zvOnlxZLeNph">The Note carries a <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_c20220331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember_zXAPbDA4RDbj">12.5% interest rate with interest only payable monthly from April through August 2022. The Company received $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfDebt_c20220301__20220331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember_zQK5AmEpwOj9">874,286 in cash, net of the OID of $<span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20220331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember_zlfz6ridy1el">142,857and legal and other fees in the amount of $125,714. The Note was issued to Puritan Partners, LLC, an institutional investor. Beginning in September 2022, the Company is required to make monthly redemptions at the rate of <span id="xdx_90A_eus-gaap--DebtInstrumentRedemptionPricePercentage_pid_dp_c20220901__20220930__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember_zWz99O5pigal" title="Monthly redemptions">110% of one seventh of the original principal amount, ($179,592), plus interest. It also carries a mandatory prepayment at <span id="xdx_90F_ecustom--MandatoryPrepaymentOfOriginalPrincipalAmount_pid_dp_c20220901__20220930__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember_zZQate5D4Em8" title="Mandatory prepayment of original principal amount, percentage">125% of the original principal amount, or $<span id="xdx_909_eus-gaap--DebtDefaultLongtermDebtAmount_iI_c20220930__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember_zzdYx8cifAVk" title="Debt instrument, long term debt">1,428,571, less any redemptions made, upon the completion of a Qualified Offering, as defined. The Note is convertible into common stock of the Company upon an event of default, as defined. The lender received five-year warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220930__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember_zQCg5olCPkZk">22,857,143 shares of common stock of the Company, with an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220930__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember_zUSSN3YSCj27">0.0001 per share. These warrants were recorded as debt discount in the amount of $<span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20220930__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__us-gaap--SeniorNotesMember_zPfBnoOPCLak">1.0 million which will be amortized over the term of the Note. The warrants can be exercised on a cash-less basis if a registration statement for the common shares underlying the warrants is not declared effective by September 2022. The Note is secured by all the tangible and intangible assets of the Company. (c) Deficiency in Stockholders Equity Subsequent to December 31, 2021 the Company issued 1,000,000 shares of common stock valued at $51,750, as a bonus to an officer of the Company. In January 2022, the $25,000 common stock subscription was received. (d) Options In January 2022, the Company issued to three employees an aggregate of <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_pid_c20220131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--ThreeEmployeesMember_zLQ2zFhFoFyh">7,465,500 <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220101__20220131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--ThreeEmployeesMember_zils3UAyHBv2" title="::XDX::P5Y">five-year term Options at a strike price of $<span id="xdx_907_eus-gaap--SharePrice_iI_pid_c20220131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--ThreeEmployeesMember_zsOiVtOrVfFa" title="Share price">0.05175 to purchase $<span id="xdx_904_eus-gaap--PaymentsForRepurchaseOfCommonStock_c20220101__20220131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--ThreeEmployeesMember_z5gnbeB8tPm7" title="Payments to purchase common stock">155,250 worth of common shares, as a bonus to Company officers and employees.

1142857

0.125

The Note carries a 12.5% interest rate with interest only payable monthly from April through August 2022

0.125

874286

142857

125714

1.10

179592

1.25

1428571

22857143

0.0001

1000000.0

1000000

51750

25000

7465500

0.05175

155250

126850

670263

25000

64808

58642

191658

753905

6834

342

114

6492

6720

204015

92975

1631705

1558550

1835720

1651525

2033870

2412150

1352265

726904

12594 3431

380952

200000

1945811

730335

1945811

730335

30000000

18065735

18043557

0.0001

200000000

81000

0.0001

1100000000

571651636

570651636

57165

57065

11588070

10498221

-29622919

-26917036

-17977676

-16361742

2033870

2412150

407697

2490597

1155344

3099185

553692

95141

1092453

95141

15000

1990

2005

3979

2765

963379

2587743

2251776

3212091

-963379

-2587743

-2251776

-3212091

324106

8011

431928

176672

-324106

-8011

-431928

-176672

-1287485

-2595754

-2683704

-3388763

566946

22179

12182310

-1287485

-3162700

-2705883

-15571073

-0.00 -0.01 -0.00 -0.03 571651636 529253750 571474288 452174976

570651636

30081000

57065

10498221

-26917036

-16361742

1000000

100

51650

51750

155250

869973

12976 12976

22179

-2683704

571651636

30081000

57165

11588070

-29622919

-17977676

333000327

164402750

33300

3544658

-8099627

-4521640

333000327

164402750

33300

3544658

-8099627

-4521640

27066666 -203000 2707 -21 -2686

135836702

-134109750

13584

1550667

1564251

9533 9533 296543 296543 10000000 1000 599000 600000 375000 37 11212 11249

7715000

771

429656

430427

10937499

1094

655156

656250

10500000 1050 523950 525000 1000000 100 7300 7400

12182310

-3388763

536431194

30090000

53643

7624989

-23670700

-15992060

536431194

30090000

53643

7624989

-23670700

-15992060

-2683704

-3388763

3979

2765

261662

2552595

47619

132129

333333 53842

15000

-25000

-70000

13991

28249

529708

-20253

1950

-1496394

-608984

40632

8500

-40632

-8500

600000

525000

50000

52021

111040

869972

286702 110000

993613

1185000

-543413

567516

670263

160607

126850

728123

50977

10000

22179 12182310

NOTE 1 - NATURE OF OPERATIONS Curative Biotechnology Inc. (f/k/a Connectyx Technologies Holdings Group, Inc.), (CUBT), is a Florida corporation, formed as a Nevada corporation on June 29, 1995, reincorporated in Florida on October 30, 2007, with a name change November 30, 2020, which conducts business from its headquarters in Boca Raton, Florida. Curative Biotechnology, Inc. is a development stage biomedical company that seeks to develop, in-license, sub-license and bring to market products in both the Pharmaceutical and Medical Device space. The Company focuses on products that are targeted at FDA-defined “Orphan Diseases” with patient populations under 200,000 in the United States. The company leverages management’s experience and business relationships with Life Science research institutions as well as Life Science industry members to acquire Life Science candidates that fit within the company’s business model. The company has established a scientific advisory board with a successful track record of bringing pharmaceuticals to market.

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (a) Basis of Presentation The accompanying condensed interim financial statements have been prepared without audit in accordance with Generally Accepted Accounting Principles (“GAAP”) in the United States of America (“U.S.”) as promulgated by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). In our opinion, the accompanying unaudited interim financial statements contain all adjustments (which are of a normal recurring nature) necessary for a fair presentation. Operating results for the six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. Certain comparative period items have been reclassified to conform with the current period presentation. (b) Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. (c) Cash and equivalents For purposes of the statement of cash flows, the Company considers all highly liquid investments with maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents at June 30, 2022 and December 31, 2021. (d) Prepaid expenses From time to time, the Company may prepay expenses either through the transfer of cash, assets or the issuance of securities. Prepaid expenses are amortized over the period of benefit. (e) Property and equipment All property and equipment are recorded at cost and depreciated over their estimated useful lives, using the straight-line method. Upon sale or retirement, the cost and related accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in the results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred. (f) Intangible Assets The useful life of intangible assets is assessed as either finite or indefinite. Following the initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses, if any. Intangible assets with finite useful lives are carried at cost less accumulated amortization. Amortization is calculated using the straight line method over the estimated useful lives. Intangible assets with indefinite useful lives are not amortized, but are tested for impairment annually. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis. If impairment indicators are present, these assets are subject to an impairment review. Any loss resulting from impairment of intangible assets is expensed in the period the impairment is identified. Curative Biotechnology, Inc Notes to Condensed Financial Statements (Unaudited) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued (g) Impairment of Long-Lived Assets A long-lived asset is tested for impairment whenever events or changes in circumstances indicate that its carrying value amount may not be recoverable. An impairment loss is recognized when the carrying amount of the asset exceeds the sum of the undiscounted cash flows resulting from its use and eventual disposition. The impairment loss is measured as the amount by which the carrying amount of the long-lived assets exceeds its fair value. (h) Financial Instruments and Fair Value Measurements ASC 825-10 “Financial Instruments”, allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments. ASC 825 also requires disclosures of the fair value of financial instruments. The carrying value of the Company’s current financial instruments, which include cash and cash equivalents, accounts payable and accrued liabilities approximates their fair values because of the short-term maturities of these instruments. FASB ASC 820 “Fair Value Measurement” clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. It also requires disclosure about how fair value is determined for assets and liabilities and establishes a hierarchy for which these assets and liabilities must be grouped, based on significant levels of inputs as follows: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability. Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement. (i) Related Party Transactions All transactions with related parties are in the normal course of operations and are measured at the exchange amount. (j) Revenue Recognition The Company adopted Accounting Standards Codification, (“ASC”), 606, “Revenue from Contracts with Customer” on January 1, 2018. This revenue recognition standard has a five step process: a) Determine whether a contract exists; b) Identify the performance obligations; c) Determine the transaction price; d) Allocate the transaction price; e) Recognize revenue when (or as) performance obligations are satisfied. The Company’s financial statements are prepared under the accrual method of accounting. Revenues will be recognized when pervasive evidence of an arrangement exists, services have been rendered (product delivered), the sales price is fixed or determinable, and collectability is reasonably assured. This occurs only when the product(s) is ordered and subsequently delivered. (k) Stock based compensation Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award. The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. Pursuant to ASC 505-50, for share-based payments to non-employees, compensation expense is determined at the “measurement date.” The expense is recognized over the service period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the measurement date. Curative Biotechnology, Inc Notes to Condensed Financial Statements (Unaudited) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued (l) Income Taxes Provisions for income taxes are based on taxes payable or refundable for the current year and deferred taxes on temporary differences between the amount of taxable income and pretax financial income, and between the tax bases of assets and liabilities and their reported amounts in the financial statements. Deferred tax assets and liabilities are included in the consolidated financial statements at currently enacted income tax rates applicable to the period in which the deferred tax assets and liabilities are expected to be realized or settled as prescribed in FASB ASC 740. As changes in tax laws or rates are enacted, deferred tax assets and liabilities are adjusted through the provision for income taxes. Tax positions initially need to be recognized in the financial statements when it is more-likely-than-not the positions will be sustained upon examination by the tax authorities. (m) Net loss per share Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the Company. Diluted loss per share is computed by dividing the loss available to stockholders by the weighted average number of shares outstanding for the period and dilutive potential shares outstanding unless consideration of such dilutive potential shares would result in anti-dilution. There were no dilutive common stock equivalents for the periods ended June 30, 2022 and 2021.

(a) Basis of Presentation The accompanying condensed interim financial statements have been prepared without audit in accordance with Generally Accepted Accounting Principles (“GAAP”) in the United States of America (“U.S.”) as promulgated by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). In our opinion, the accompanying unaudited interim financial statements contain all adjustments (which are of a normal recurring nature) necessary for a fair presentation. Operating results for the six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. Certain comparative period items have been reclassified to conform with the current period presentation.

(b) Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

(c) Cash and equivalents For purposes of the statement of cash flows, the Company considers all highly liquid investments with maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents at June 30, 2022 and December 31, 2021.

(d) Prepaid expenses From time to time, the Company may prepay expenses either through the transfer of cash, assets or the issuance of securities. Prepaid expenses are amortized over the period of benefit.

(e) Property and equipment All property and equipment are recorded at cost and depreciated over their estimated useful lives, using the straight-line method. Upon sale or retirement, the cost and related accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in the results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred.

(f) Intangible Assets The useful life of intangible assets is assessed as either finite or indefinite. Following the initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses, if any. Intangible assets with finite useful lives are carried at cost less accumulated amortization. Amortization is calculated using the straight line method over the estimated useful lives. Intangible assets with indefinite useful lives are not amortized, but are tested for impairment annually. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis. If impairment indicators are present, these assets are subject to an impairment review. Any loss resulting from impairment of intangible assets is expensed in the period the impairment is identified. Curative Biotechnology, Inc Notes to Condensed Financial Statements (Unaudited) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued

(g) Impairment of Long-Lived Assets A long-lived asset is tested for impairment whenever events or changes in circumstances indicate that its carrying value amount may not be recoverable. An impairment loss is recognized when the carrying amount of the asset exceeds the sum of the undiscounted cash flows resulting from its use and eventual disposition. The impairment loss is measured as the amount by which the carrying amount of the long-lived assets exceeds its fair value.

(h) Financial Instruments and Fair Value Measurements ASC 825-10 “Financial Instruments”, allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments. ASC 825 also requires disclosures of the fair value of financial instruments. The carrying value of the Company’s current financial instruments, which include cash and cash equivalents, accounts payable and accrued liabilities approximates their fair values because of the short-term maturities of these instruments. FASB ASC 820 “Fair Value Measurement” clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. It also requires disclosure about how fair value is determined for assets and liabilities and establishes a hierarchy for which these assets and liabilities must be grouped, based on significant levels of inputs as follows: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability. Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

(i) Related Party Transactions All transactions with related parties are in the normal course of operations and are measured at the exchange amount.

(j) Revenue Recognition The Company adopted Accounting Standards Codification, (“ASC”), 606, “Revenue from Contracts with Customer” on January 1, 2018. This revenue recognition standard has a five step process: a) Determine whether a contract exists; b) Identify the performance obligations; c) Determine the transaction price; d) Allocate the transaction price; e) Recognize revenue when (or as) performance obligations are satisfied. The Company’s financial statements are prepared under the accrual method of accounting. Revenues will be recognized when pervasive evidence of an arrangement exists, services have been rendered (product delivered), the sales price is fixed or determinable, and collectability is reasonably assured. This occurs only when the product(s) is ordered and subsequently delivered.

(k) Stock based compensation Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award. The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. Pursuant to ASC 505-50, for share-based payments to non-employees, compensation expense is determined at the “measurement date.” The expense is recognized over the service period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the measurement date. Curative Biotechnology, Inc Notes to Condensed Financial Statements (Unaudited) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued

(l) Income Taxes Provisions for income taxes are based on taxes payable or refundable for the current year and deferred taxes on temporary differences between the amount of taxable income and pretax financial income, and between the tax bases of assets and liabilities and their reported amounts in the financial statements. Deferred tax assets and liabilities are included in the consolidated financial statements at currently enacted income tax rates applicable to the period in which the deferred tax assets and liabilities are expected to be realized or settled as prescribed in FASB ASC 740. As changes in tax laws or rates are enacted, deferred tax assets and liabilities are adjusted through the provision for income taxes. Tax positions initially need to be recognized in the financial statements when it is more-likely-than-not the positions will be sustained upon examination by the tax authorities.

(m) Net loss per share Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the Company. Diluted loss per share is computed by dividing the loss available to stockholders by the weighted average number of shares outstanding for the period and dilutive potential shares outstanding unless consideration of such dilutive potential shares would result in anti-dilution. There were no dilutive common stock equivalents for the periods ended June 30, 2022 and 2021.

NOTE 3 - LIQUIDITY AND GOING CONCERN CONSIDERATIONS The accompanying interim condensed financial statements have been prepared assuming that the Company will continue as a going concern. The Company’s financial position and operating results raise substantial doubt about the Company’s ability to continue as a going concern, as reflected by the net loss of approximately $2.7 million, accumulated deficit of approximately $29.6 million through June 30, 2022 and a deficiency in working capital of approximately $1.8 million at June 30, 2022. The ability of the Company to continue as a going concern is dependent upon commencing operations, developing sales and obtaining additional capital and financing. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The Company is currently seeking additional capital to allow it to grow its operations

-2700000

-29600000

1800000

NOTE 4 - INTANGIBLE ASSETS During the 4th quarter 2021, the Company acquired the following intangible asset: (a) MABT Covid-19 license The Company entered into a licensing agreement with Mid-Atlantic BioTheraputics, Inc., (MABT), to license MABT’s COVID-19 vaccine which is composed of a recombinant S1 and S2 protein from SARS-CoV-2 plus an IMT504 adjuvant. The Company issued 12,500,000 shares of common stock valued at $1,425,000 to acquire this license. During the 4th quarter 2020, the Company acquired the following intangible assets: (b) Website In December 2020, the Company contracted with a third party to develop and produce a new website for the Company for a contract price of $22,500, one-half in cash and one-half in common stock of the Company. The Company is amortizing this cost over 3 years. This website was placed into service in March 2021. Amortization expense for the six months ended June 30, 2022 was $3,750. (c) Patent rights option In October 2020, the Company entered into an agreement for the option to purchase certain exclusive license rights for US Patent No. 8,287,505 Ophthalmic Drop Dispensing Tip Assembly, issued October 16, 2012, from IEM, Inc., (IEM), the sole owner of this patent. The cost of this option was $1,800. Curative Biotechnology, Inc Notes to Condensed Financial Statements (Unaudited) NOTE 4 - INTANGIBLE ASSETS, continued (c) Patent rights option, continued The Company had until September 30, 2021, to advise IEM in writing that it wishes to exercise this Option Right and pay IEM $<span id="xdx_903_eus-gaap--PaymentsToAcquireIntangibleAssets_c20210901__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__dei--LegalEntityAxis__custom--IEMIncMember_pp0p0">50,000 in exchange for an exclusive world-wide, royalty free perpetual license. In September 2021, the Company exercised the option to extend the deadline for notification in the contract with IEM, from September 30, 2020 to March 31, 2022, in exchange for the payment of $<span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend_c20210901__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__dei--LegalEntityAxis__custom--IEMIncMember_pp0p0">1,000. In April 2022 the Company paid $<span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend_pp0p0_c20220401__20220430__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__dei--LegalEntityAxis__custom--IEMIncMember_zBXIshrjJ8d4">1,000 for an additional six month extension. The Company is evaluating the Patent rights, potential products and markets under this Patent. (d) IMT504 Patent license In October 2020, the Company entered into a license agreement with MidAtlantic BioTheraputics, Inc., (MABT), to license the development of a pharmaceutical compound known as IMT504, as immununotherapy for late stage symptomatic rabies. The license is for worldwide use. There are certain conditions to the license, principally that the Company raise $<span id="xdx_909_ecustom--ProceedsForLicenseDevelopment_pn5n6_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__dei--LegalEntityAxis__custom--MidAtlanticBioTheraputicsIncMember_zoiLEN2NdSZe">6.5 million to fund the development. There is not a time limit on raising these funds unless the Company utilizes a public offering process, such as Regulation A. The total cost for this license is <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pn6n6_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--ProductOrServiceAxis__custom--InvestigationalNewDrugMember_zT9C457zzh96">20 million shares of the Company’s common stock, issuable in three tranches - (1) <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pn6n6_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--ProductOrServiceAxis__custom--InvestigationalNewDrugMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zBHhCWI6iK7k">7 million shares upon execution of the license (which have been issued, valued at $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_pp0p0_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--ProductOrServiceAxis__custom--InvestigationalNewDrugMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_z6onh9jIApVl">91,000), (2) <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pn5n6_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--ProductOrServiceAxis__custom--InvestigationalNewDrugMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_z8s7bKVNypA2">6.5 million shares upon the submission of an Investigational New Drug (IND) to the FDA and (3) <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pn5n6_c20201001__20201031__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--ProductOrServiceAxis__custom--InvestigationalNewDrugMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_zOvmQmhkAA2g">6.5 million shares upon the successful completion of the first rabies clinical trial of this IND. This license calls for royalties of 50% of the net profit, after reimbursement for development costs, of successfully marketed products utilizing IMT504. A principal goal of this license is to obtain a Priority Review Voucher (PRV) issued by the US FDA, and subsequently sell the PRV to a major pharmaceutical company. The Company and MABT will split the proceeds from the sale of such PRV equally. (e) National Institute of Health (NIH) Patent license #1 In October 2020, the Company entered into an exclusive 24 month evaluation license of Provisional Patent Application No. 62/199,707, filed July 31, 2015; PCT Application No. PCT/US2016/044777 filed July 29, 2016 and Patent No. 10,548,987 issued February 4, 2020. This license is for the evaluation of and development of an anti-CD56 antibody drug conjugate for the treatment of gioblastoma. Should the Company develop a marketable product, the Company is then required to negotiate a new license with market based royalties. This license calls for the payment of a non-creditable non-refundable license issue royalty of $10,000, paid ½ at issuance and ½ on the one year anniversary. (f) National Institute of Health (NIH) Patent license #2 In January 2021 the Company entered into an NIH exclusive 36 month worldwide license of Provisional Patent Application No. 62/899,899, filed September 13, 2019 and PCT Application No. PCT/US2020/050540 filed September 11, 2020. This license is for the development of ocular metformin formulation for the treatment of retinal degenerative diseases. This license requires two separate royalty streams of payments. First is a royalty equal to the unreimbursed patent expenses paid by NIH, with an initial amount of $<span id="xdx_90F_eus-gaap--RoyaltyExpense_pp0p0_c20210101__20210131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NationalInstituteOfHealthPatentLicenseTwoMember__srt--ProductOrServiceAxis__us-gaap--RoyaltyMember_zwKkqIoqjUfi">8,500 due within 30 days of execution of the license. At the first anniversary of the license NIH will supply a statement of additional unreimbursed patent expenses paid by NIH during the year, of which the Company is required to pay 50%, with the remaining balance due on the third anniversary. Curative Biotechnology, Inc Notes to Condensed Financial Statements (Unaudited) NOTE 4 - INTANGIBLE ASSETS, continued (f) National Institute of Health (NIH) Patent license #2, continued Second is an ongoing royalty schedule: an initial royalty of $<span id="xdx_904_eus-gaap--RoyaltyExpense_pp0p0_c20210101__20210131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NationalInstituteOfHealthPatentLicenseTwoMember__srt--ProductOrServiceAxis__custom--RoyaltyOneMember_zLACvxlTalde">5,000 upon execution of the license, and annually thereafter as the minimum royalty amount. <span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetsIntentOrAbilityToRenewOrExtendArrangement_c20210101__20210131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NationalInstituteOfHealthPatentLicenseTwoMember__srt--ProductOrServiceAxis__custom--RoyaltyOneMember_zkfPbmAAlnY9">The license can be extended on the third anniversary to the remaining life of the licensed patent by the payment of a one-time non-refundable non-creditable royalty of $<span id="xdx_901_eus-gaap--PaymentsForRoyalties_pp0p0_c20210101__20210131__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NationalInstituteOfHealthPatentLicenseTwoMember__srt--ProductOrServiceAxis__custom--RoyaltyOneMember_zvzt0TRMKQ22">45,000. There are three benchmark royalties - $75,000 upon the initiation of the first Phase 2 Clinical Study; $300,000 upon the completion of Phase 3 Clinical Study and $600,000 upon the FDA approval of the first Licensed Product. Upon first commercial sale there is a royalty of $100,000 each for the United States, Canada, European Union and Asian region. Last is a 3.5% of net sales royalty.

12500000

1425000

22500

P3Y

3750

1800

50000

1000

6500000

20000000

7000000

91000

6500000

10000

8500

5000

The license can be extended on the third anniversary to the remaining life of the licensed patent by the payment of a one-time non-refundable non-creditable royalty of $45,000. There are three benchmark royalties - $75,000 upon the initiation of the first Phase 2 Clinical Study; $300,000 upon the completion of Phase 3 Clinical Study and $600,000 upon the FDA approval of the first Licensed Product. Upon first commercial sale there is a royalty of $100,000 each for the United States, Canada, European Union and Asian region. Last is a 3.5% of net sales royalty.

45000

NOTE 5 - RELATED PARTY TRANSACTIONS From time to time the Company may enter into non-arms length transactions with related parties, however the Company exercises its best efforts to ensure that such transactions are valued on a basis comparable to a true arms length transaction. During the second quarter of 2021, the remaining two notes from officers of the Company, totaling $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210630__us-gaap--DebtInstrumentAxis__custom--TwoNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_za40mTPbbhwh">40,000 of principal and $<span id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20210630__us-gaap--DebtInstrumentAxis__custom--TwoNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_zLdlhtgG0vg8">10,000 of OID, were repaid in cash.

40000

10000

NOTE 6 - NOTES PAYABLE During the second quarter of 2022, the Company issued a promissory note in exchange for $200,000 in cash. This note carries a <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPercent_c20220630__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteExchangeMember_zj1eiuFyxyqf" title="Notes payable interest rate">12% interest rate, interest payable monthly, and a six month maturity. During the quarter ended March 31, 2022, the Company entered into a financing for the purchase of a Directors and Officers (D&O) Liability Insurance policy. This financing carries a 5.65% interest rate and is payable monthly for 10 months. At June 30, 2022, the outstanding balance on this note was $34,681. During the second quarter of 2021, the then remaining two notes, totaling $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210630__us-gaap--DebtInstrumentAxis__custom--TwoNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_zUlrk37R2rof">40,000 of principal and $<span id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20210630__us-gaap--DebtInstrumentAxis__custom--TwoNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_z82VnZaCRIg5">10,000 of OID, were repaid in cash. During the first quarter of 2021, 13 of the 15 note holders converted their note receivable into shares of common stock at the rate of $0.06 per share, for a total of 10,937,499 shares of common stock for a total of $656,250 convertible debt. During the first quarter of 2021, the Company entered into 2 notes payable for a total amount of cash received of $110,000. The notes are identical and carry a maturity of six months from inception and a 25% original issue discount (OID). The maturity was extendable at the Company’s option for up to three months with a 3% per month extension fee. The notes also carried 10 warrants for each $<span id="xdx_900_ecustom--WarrantLoaned_iI_pp0p0_c20210331__us-gaap--DebtInstrumentAxis__custom--TwoNotesPayableMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z1VJlpVcx5A3">1 loaned. These notes were collateralized by Preferred C shares representing 2.64% of the issued and outstanding common stock shares. Two officers holding Preferred C shares have pledged the Preferred C shares as this collateral.

200000

This note carries a 12% interest rate, interest payable monthly, and a six month maturity.

0.12

0.0565

34681

40000

10000

0.06

10937499

656250

110000

0.25

1 0.0264

NOTE 7 - CONVERTIBLE SENIOR SECURED NOTE PAYABLE In March 2022, the Company issued a 12-month Senior Secured Note with a face amount of $1,142,857, with a stated <span id="xdx_90E_eus-gaap--DebtConversionOriginalDebtInterestRateOfDebt_pid_dp_c20220301__20220331__us-gaap--DebtInstrumentAxis__custom--TwelveMonthSeniorSecuredNoteMember_z7KfOFPcLUme" title="Debt instrument original interest rate">12.5% original issue discount (OID). The Note carries a <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20220331__us-gaap--DebtInstrumentAxis__custom--TwelveMonthSeniorSecuredNoteMember_zDYjE5h6ekNg" title="Debt interest rate">12.5% interest rate with interest-only payable monthly from April through August 2022. The Company received $869,972 in cash, net of the OID of $142,857 and legal and other fees in the amount of $125,714. Beginning in September 2022, the Company is required to make monthly redemptions at the rate of <span id="xdx_903_eus-gaap--DebtInstrumentRedemptionPricePercentage_pid_dp_c20220101__20220630__us-gaap--AwardDateAxis__custom--BeginningInSeptemberTwoThousandAndTwentyTwoMember_ziVPpYlTDgok" title="Debt instrument redemption percentage">110% of one seventh of the original principal amount, ($<span id="xdx_903_eus-gaap--DebtConversionOriginalDebtAmount1_c20220101__20220630__us-gaap--AwardDateAxis__custom--BeginningInSeptemberTwoThousandAndTwentyTwoMember_zK97wEFvI1na" title="Debt conversion, original debt, amount">179,592), plus interest. It also carries a mandatory prepayment at <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20220630__us-gaap--AwardDateAxis__custom--BeginningInSeptemberTwoThousandAndTwentyTwoMember_zBJgvA5Oc1Q9" title="Debt interest rate">125% of the original principal amount, or $<span id="xdx_909_eus-gaap--PreferredStockRedemptionDiscount_c20220101__20220630__us-gaap--AwardDateAxis__custom--BeginningInSeptemberTwoThousandAndTwentyTwoMember_z9eufOm9GNcd" title="Debt redemption amount">1,428,571, less any redemptions made, upon the completion of a Qualified Offering, as defined. Curative Biotechnology, Inc Notes to Condensed Financial Statements (Unaudited) NOTE 7 - CONVERTIBLE SENIOR SECURED NOTE PAYABLE, continued The Note is convertible into common stock of the Company upon an event of default, as defined. The lender received five year warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220630__us-gaap--AwardDateAxis__custom--BeginningInSeptemberTwoThousandAndTwentyTwoMember_zKmJSMcXuqP6" title="Number of warrant shares">22,857,143 shares of common stock of the Company, with an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220630__us-gaap--AwardDateAxis__custom--BeginningInSeptemberTwoThousandAndTwentyTwoMember_zDIYIFfYXCug" title="Class of warrant exercise price per share">0.0001 per share. These warrants were recorded as debt discount in the amount of $0.9 million which is being amortized over the term of the Note. The warrants can be exercised on a cash-less basis if a registration statement for the common shares underlying the warrants is not declared effective by September 2022. The Note is secured by all the tangible and intangible assets of the Company. Subsequent to June 30, 2022, certain of the terms of the Note were modified.

1142857

0.125

869972

142857

125714

1.10

179592

1.25

1428571

22857143

0.0001

900000

NOTE 8 – DEFICIENCY IN STOCKHOLDERS EQUITY At June 30, 2022 and December 31, 2021, the Company has 1,100,000,000 shares of par value $0.0001 common stock authorized and 571,651,636 and 570,651,636 issued and outstanding, respectively. At June 30, 2022 and December 31, 2021, the Company has 200,000,000 shares of $0.0001 par value preferred stock authorized. The Series A and Series C preferred stock has been accounted for in accordance with FASB Accounting Standards Codification (ASC) 480, as mezzanine equity due to Series A having a redemption provision by the holder and Series C being convertible into a variable number of common shares. SCHEDULE OF STOCKHOLDERS EQUITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B5_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesAPreferredStockMember_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zHehh8Abwjm5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B5_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesBPreferredStockMember_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zOZSdckOhLob" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B3_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesCPreferredStockMember_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zAP9n8LfrGTi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--SeriesABCPreferredStockMember_z68gB7OrbpF1" style="border-bottom: Black 1.5pt solid; font-weight: bold">Par</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series A</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series B</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series C</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold">Par</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_432_c20210101__20211231_eus-gaap--StockholdersEquity_iS_zwOMeZNYkLrj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%">January 1, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zLdzz6FIPrmc" style="width: 5%; text-align: right" title="Beginning balance, shares">134,109,750</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">13,411</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zw8F6fzU6RS4" style="width: 5%; text-align: right">293,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">29</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zdVy5xUVoOq2" style="width: 5%; text-align: right">30,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">3,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesABCPreferredStockMember_zl1UrYBnZjAj" style="width: 5%; text-align: right">164,402,750</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">16,440</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_znGlIqkNsav9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Conversion to common shares</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z8r0dtAAv3L6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversion to common shares, shares">(134,109,750</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,411</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zVbzKSp7LTFl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversion to common shares, shares">(212,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zrXdLekVGSB5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversion to common shares, shares">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesABCPreferredStockMember_zxUCD5vn5NYf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversion to common shares, shares">(134,321,750</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,432</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_436_c20220101__20220630_eus-gaap--StockholdersEquity_iS_zJrAFmLcTKvc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zvGarWTy2XA" style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zVuh0y9CxwFk" style="text-align: right">81,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zHSLqJD67Bfc" style="text-align: right">30,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesABCPreferredStockMember_zanYz1ZRQhFf" style="text-align: right">30,081,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,008</td><td style="text-align: left"> </td></tr> <tr id="xdx_432_c20220101__20220630_eus-gaap--StockholdersEquity_iS_zAuFawvjvp77" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Beginning balance, value</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zVv9iYC4N0Ug" style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zPwYl5kqq2e3" style="text-align: right">81,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_ztGIal9jVdo6" style="text-align: right">30,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesABCPreferredStockMember_zYh40va3h8o9" style="text-align: right">30,081,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,008</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueOther_zvY6fbxgi58k" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">no transactions</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesOther_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zTcnSmjZfI44" style="border-bottom: Black 1.5pt solid; text-align: right" title="no transactions, shares">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesOther_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z5Va6WMKZ9Bf" style="border-bottom: Black 1.5pt solid; text-align: right" title="no transactions, shares">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesOther_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zoXxJNz4h37h" style="border-bottom: Black 1.5pt solid; text-align: right" title="no transactions, shares">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesABCPreferredStockMember_zajToe1oyrxb" style="border-bottom: Black 1.5pt solid; text-align: right" title="no transactions, shares">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_433_c20220101__20220630_eus-gaap--StockholdersEquity_iE_zWgq0icHfML" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">June 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ziVv3rP49lil" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance shares">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zA8bE5m9Hkc5" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance shares">81,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zVWHbW5SfQu9" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance shares">30,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesABCPreferredStockMember_zL3T8Vcxu1wd" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance shares">30,081,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,008</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_43D_c20220101__20220630_eus-gaap--StockholdersEquity_iE_zxp7yfubFLo5" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Ending balance, value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zxBJlKylhpRi" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance shares">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_ztCwzELVTtlg" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance shares">81,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zs1ZcSW3I6wh" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance shares">30,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesABCPreferredStockMember_z1ks6NhQZ9xe" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance shares">30,081,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,008</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The preferred shares have the following respective rights and privileges: Series A Preferred carry 10 votes for each share of common stock that each Series A shares are convertible into at the record date; is convertible into common stock aggregating <span id="xdx_903_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPercent_c20220101__20220630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zkjGfgDPyMG5">35% of the total issued and outstanding common shares at conversion date post conversion; are redeemable for the greater of 45% of the total market value of the common share or the calculation of the book value of the Company made by an independent audit firm or $5,000,000. During the first quarter of 2021, all of the Series A was converted into <span id="xdx_909_eus-gaap--ConversionOfStockSharesIssued1_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zgrWxvn01IPj">135,836,702 shares of common stock. Series B Preferred are convertible in common shares of common stock at a conversion price of $0.0075 per share; are redeemable at a price of 125% of the purchase price paid for the shares; carry one vote for each common share that the Series B is convertible into at the record date; are senior to all other securities in the event of a liquidation. During the first quarter of 2021, 203,000 shares of the Series B was converted into 27,066,666 shares of common stock. Curative Biotechnology, Inc. Notes to Condensed Financial Statements (Unaudited) NOTE 8 – DEFICIENCY IN STOCKHOLDERS EQUITY, continued Series C Preferred are convertible into at the record date; is convertible into common stock aggregating 30% of the total issued and outstanding common shares at conversion date post conversion; carry one vote for each common share that the Series C is convertible into at the record date. Quarter ended March 31, 2022: The Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210401__20210630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zTTaD2DgBUKk" title="Number of shares issued for service shares">1,000,000 shares of common stock to one employee for past services valued at $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220101__20220331__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8bHXnCkSeI" title="Number of shares issued for service value">51,750. Quarter ended December 31, 2021: The Company issued 13,159,331 shares of common stock and 25,915,437 warrants for the purchase of common stock in exchange for $523,000 in cash and $25,000 in deposit in transit. The Company issued 200,000 shares of common stock, valued at $21,960 for services. The Company issued 12,500,000 shares of common stock, valued at $1,425,000 for the license to MABT’s COVID-19 vaccine. Quarter ended September 30, 2021: The Company issued 4,361,111 shares of common stock and 4,236,111 warrants for the purchase of common stock in exchange for $425,000 in cash. The Company issued 250,000 shares of common stock, valued at $22,500, to an individual for services to be rendered as a member of the Company’s Advisory Board. These shares vest 60,000 immediately, 60,000 in December 2021, <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20220401__20220430__srt--TitleOfIndividualAxis__custom--AdvisoryBoardMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zqDXoUP68c81">60,000 in April 2022 and <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20220801__20220831__srt--TitleOfIndividualAxis__custom--AdvisoryBoardMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zB6Re5viDG19">70,000 in August 2022. The Company issued 300,000 shares of common stock, valued at $36,720, to an individual for services rendered as a member of the Company’s Board of Directors. The Company issued 250,000 shares of common stock, valued at $28,475, to an individual for services to be rendered as a member of the Company’s Advisory Board. These shares vested immediately. The Company issued 2,000,000 shares of common stock, valued at $180,000, to settle the lawsuit brought to enforce the convertible note. 9,000 shares of the Series B preferred stock was converted into 1,200,000 shares of common stock. Quarter ended June 30, 2021: The Company issued 10,000,000 shares of common stock and 5,000,000 warrants for the purchase of common stock in exchange for $600,000 in cash. The warrants mature in May 2026, and carry an exercise price of $0.11 per share. The Company issued 1,000,000 shares of common stock to settle the liability to issue shares. Quarter ended March 31, 2021: The Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeForServicesMember_zkEjmp1YCgF">125,000 shares of common stock in exchange for services valued at $<span id="xdx_909_ecustom--StockIssuedDuringPeriodValueExchangeForServices_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeForServicesMember_zkueon7h2h44">5,575, or $0.0446 per share. The Company issued 375,000 shares of common stock to settle a payable in the amount of $11,250. All of the Series A preferred stock was converted into 135,836,702 shares of common stock. 203,000 shares of the Series B preferred stock was converted into 27,066,666 shares of common stock. 13 of the 15 note holders converted their note receivable into shares of common stock at the rate of $0.06 per share, for a total of 10,937,499 shares of common stock for a total of $656,250 convertible debt. The Company issued 10,500,000 shares of common stock upon receipt of $525,000 in cash for the exercise of 10,500,000 warrants. The Company issued 6,500,000 shares of common stock for the exercise of 6,500,000 warrants in exchange for services valued at $325,000.

1100000000

0.0001

571651636

570651636

200000000

0.0001

The Series A and Series C preferred stock has been accounted for in accordance with FASB Accounting Standards Codification (ASC) 480, as mezzanine equity due to Series A having a redemption provision by the holder and Series C being convertible into a variable number of common shares. SCHEDULE OF STOCKHOLDERS EQUITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B5_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesAPreferredStockMember_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zHehh8Abwjm5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B5_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesBPreferredStockMember_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zOZSdckOhLob" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B3_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesCPreferredStockMember_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zAP9n8LfrGTi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--SeriesABCPreferredStockMember_z68gB7OrbpF1" style="border-bottom: Black 1.5pt solid; font-weight: bold">Par</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series A</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series B</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series C</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold">Par</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_432_c20210101__20211231_eus-gaap--StockholdersEquity_iS_zwOMeZNYkLrj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%">January 1, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zLdzz6FIPrmc" style="width: 5%; text-align: right" title="Beginning balance, shares">134,109,750</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">13,411</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zw8F6fzU6RS4" style="width: 5%; text-align: right">293,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">29</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zdVy5xUVoOq2" style="width: 5%; text-align: right">30,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">3,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesABCPreferredStockMember_zl1UrYBnZjAj" style="width: 5%; text-align: right">164,402,750</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">16,440</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_znGlIqkNsav9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Conversion to common shares</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z8r0dtAAv3L6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversion to common shares, shares">(134,109,750</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,411</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zVbzKSp7LTFl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversion to common shares, shares">(212,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zrXdLekVGSB5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversion to common shares, shares">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesABCPreferredStockMember_zxUCD5vn5NYf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Conversion to common shares, shares">(134,321,750</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,432</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_436_c20220101__20220630_eus-gaap--StockholdersEquity_iS_zJrAFmLcTKvc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zvGarWTy2XA" style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zVuh0y9CxwFk" style="text-align: right">81,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zHSLqJD67Bfc" style="text-align: right">30,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesABCPreferredStockMember_zanYz1ZRQhFf" style="text-align: right">30,081,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,008</td><td style="text-align: left"> </td></tr> <tr id="xdx_432_c20220101__20220630_eus-gaap--StockholdersEquity_iS_zAuFawvjvp77" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Beginning balance, value</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zVv9iYC4N0Ug" style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zPwYl5kqq2e3" style="text-align: right">81,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_ztGIal9jVdo6" style="text-align: right">30,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesABCPreferredStockMember_zYh40va3h8o9" style="text-align: right">30,081,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,008</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueOther_zvY6fbxgi58k" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">no transactions</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesOther_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zTcnSmjZfI44" style="border-bottom: Black 1.5pt solid; text-align: right" title="no transactions, shares">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesOther_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z5Va6WMKZ9Bf" style="border-bottom: Black 1.5pt solid; text-align: right" title="no transactions, shares">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesOther_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zoXxJNz4h37h" style="border-bottom: Black 1.5pt solid; text-align: right" title="no transactions, shares">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesABCPreferredStockMember_zajToe1oyrxb" style="border-bottom: Black 1.5pt solid; text-align: right" title="no transactions, shares">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_433_c20220101__20220630_eus-gaap--StockholdersEquity_iE_zWgq0icHfML" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">June 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ziVv3rP49lil" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance shares">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zA8bE5m9Hkc5" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance shares">81,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zVWHbW5SfQu9" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance shares">30,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesABCPreferredStockMember_zL3T8Vcxu1wd" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance shares">30,081,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,008</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_43D_c20220101__20220630_eus-gaap--StockholdersEquity_iE_zxp7yfubFLo5" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Ending balance, value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zxBJlKylhpRi" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance shares">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_ztCwzELVTtlg" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance shares">81,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zs1ZcSW3I6wh" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance shares">30,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesABCPreferredStockMember_z1ks6NhQZ9xe" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance shares">30,081,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,008</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

134109750

13411

293000

30000000

3000

164402750

16440

-134109750

-13411

-212000

-21

-134321750

-13432

81000

30000000

3000

30081000

3008

81000

30000000

3000

30081000

3008

81000

30000000

3000

30081000

3008

81000

30000000

3000

30081000

3008

Series A Preferred carry 10 votes for each share of common stock that each Series A shares are convertible into at the record date;

0.35

0.45

5000000

135836702

0.0075

1.25

203000

27066666

1000000

51750

13159331

25915437 523000

25000

200000

21960

12500000

1425000

4361111

4236111

425000

250000

22500

60000

70000

300000

36720

250000

28475

2000000

180000

9000

1200000

10000000

5000000

600000

2026-05

0.11

1000000

125000

5575

0.0446

375000 11250

135836702

203000

27066666

0.06

10937499

656250

10500000

525000

10500000

6500000

325000

NOTE 9 - WARRANTS Quarter ended March 31, 2022: The lender of the Convertible Senior Secured Note received five year warrants to purchase 22,857,143 shares of common stock of the Company, with an exercise price of $0.0001 per share. These warrants were recorded as debt discount in the amount of $0.9 million which will be amortized over the term of the Note. The warrants can be exercised on a cash-less basis if a registration statement for the common shares underlying the warrants is not declared effective by September 2022. Quarter ended December 31, 2021: The Company issued 403,225 warrants for the purchase of common stock of the Company in conjunction with the sale of 403,225 shares of common stock for cash. These warrants expire in December 2024 and have an exercise price of $0.11 per share. The Company issued 25,512,212 warrants for the purchase of common stock of the Company in conjunction with the sale of 12,756,106 shares of common stock for cash and subscription receivable. These warrants expire in December 2024 and have an exercise price of $0.09 and $0.15 per share. Curative Biotechnology, Inc. Notes to Condensed Financial Statements (Unaudited) NOTE 9 - WARRANTS, continued Quarter ended September 30, 2021: The Company issued 4,236,111 warrants for the purchase of common stock of the Company in conjunction with the sale of 4,361,111 shares of common stock for cash. These warrants expire in July and August 2026 and have an exercise price of $0.15 and $0.14 per share. The Company issued 1,000,000 warrants for the purchase of common stock of the Company in exchange for services as a member of the Board of Directors. These warrants expire in July 2024 and have an exercise price of $0.124 per share and have a cash-less exercise provision. These warrants were recorded at a total value of $34,382. Quarter ended June 30, 2021: The Company issued 5,000,000 warrants for the purchase of common stock of the Company in conjunction with the sale of 10,000,000 shares of common stock for cash. These warrants expire in May 2026 and have an exercise price of $0.11 per share. The Company issued 5,000,000 warrants for the purchase of common stock of the Company in exchange for services as a member of the Board of Directors. These warrants expire in June 2024 and have an exercise price of $0.20 per share. The warrants were recorded at a total value of $87,249. The Company issued 3,000,000 warrants for the purchase of common stock of the Company in exchange for legal services. These warrants expire in May 2026 and have an exercise price of $0.10 per share. The warrants were recorded at a total value of $155,717. The Company issued 1,000,000 warrants for the purchase of common stock of the Company in exchange for services. These warrants expire in May 2026 and have an exercise price of $0.10 per share. The warrants were recorded at a total value of $51,906 and vest <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20220501__20220531__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zk58VDhQz0z7">250,000 shares on May 20, 2021 and September 20, 2021, January 20, 2022 and May 20, 2022. Quarter ended March 31, 2021: The Company issued 10,500,000 shares of common stock upon receipt of $525,000 in cash for the exercise of 10,500,000 warrants. The Company issued 6,500,000 shares of common stock in exchange for services valued at $325,000 for the exercise of 6,500,000 warrants. The Company issued 1,100,000 warrants for the purchase of common stock of the Company in conjunction with the short term debt at the rate of 10 warrants for each $1 loaned. These warrants carry an expiration of thirty six months from issuance; an exercise price of $0.05 per share and are exercisable immediately. The warrants were recorded at a total value of $9,533. The Company issued 5,000,000 warrants for services. These warrants carry an expiration of 60 months from issuance and an exercise price of $0.05 per share. The warrants were recorded at a total value of $40,600. The method utilized to value the warrants was the Black-Scholes model with the following assumption ranges: Expected life - three or five years; stock price between $0.04 and $0.10; volatility between <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_zOUeEG2X1nsl">60.51 and <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_zu5w277zBOPh">31.56; exercise price between $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20210331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--BlackScholesMember_zlp3sdqRUbO7">0.0001 and $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20210331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_z6AWc9zqT3te">0.20 and bond equivalent yield rate between <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_zEkdUDUVCna">0.09% and <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_zCC8RjN9S8o6">0.83%.

22857143

0.0001

900000

403225

2024-12

0.11

25512212

12756106

2024-12

0.09

0.15

4236111

4361111

0.15

0.14

1000000

0.124

34382

5000000

10000000

2026-05

0.11

5000000

0.20

87249

3000000

155717

1000000

0.10

51906

250000

10500000

525000

10500000

6500000

325000

6500000

1100000

0.05

9533

5000000

0.05

40600

P5Y

0.04

0.10

0.6051

0.3156

0.0001

0.20

0.0009

0.0083

NOTE 10 - OPTIONS Quarter ended March 31, 2022: The Company issued 7,456,500 options to purchase shares of common stock equally to three employees for past services, valued at $155,250. These options have an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20220331__srt--TitleOfIndividualAxis__custom--ThreeEmployeesMember_zs75CA0oQRX1">0.05175 and a <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220101__20220331__srt--TitleOfIndividualAxis__custom--ThreeEmployeesMember_zzPGUAuLTrMd" title="::XDX::P5Y">five year life. Quarter ended September 30, 2021: The Company issued options in conjunction with an agreement for Board of Advisor services and the evaluation of certain potential intangible asset acquisitions. These options call for an undivided 1% of the fully diluted issued and outstanding shares upon exercise. These options amounted to 8,081,037 shares at issuance date. These option s contain a single recalculation upon the completion of a reverse split of the existing common stock and the Company raising a minimum of $5 million in an offering. These options carry an exercise price of $0.11 per share and expire in September 2031. These options were valued at $436,908 and vest 50% upon issuance and <span id="xdx_900_ecustom--OptionsVestedPercentage_pid_dp_uPercent_c20220901__20220930__srt--TitleOfIndividualAxis__custom--BoardOfAdvisoryMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zW9ErQNj2YZc">50% in September 2022. The method utilized to value the options was the Black-Scholes model with the following assumption ranges: Expected life - ten years; stock price $0.114; volatility 35.13; exercise price $0.11 and bond equivalent yield rate 1.47%. Curative Biotechnology, Inc Notes to Condensed Financial Statements (Unaudited)

7456500

155250

0.05175

0.01

8081037

5000000

0.11

436908

0.50 0.50

P10Y

0.114

0.3513

0.11

0.0147

NOTE 11 - EQUITY INCENTIVE PLAN On August 26, 2021, the Company adopted a equity incentive plan providing for the issuance of shares of common stock, options or SARs with a rolling maximum number equal to 10% of the issued and outstanding Common Shares set at the beginning of each fiscal year. The Company may grant incentives to its directors, officers, employees and service providers. The options are exercisable for a maximum of up to ten years from the date of grant and may be subject to vesting provisions as set by the Plan Administrator. During the quarter ended March 31, 2022, a total of 1,000,000 shares of common stock and <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20220331__srt--TitleOfIndividualAxis__custom--EmployeesMember_zqIE79bNwY29" title="Number of options, Granted">7,456,500 options at a weighted-average exercise price of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20220331__srt--TitleOfIndividualAxis__custom--EmployeesMember_zg9SRuzrLgzc" title="Weighted average exercise price, granted">0.0518 per share were granted to employees exercisable for a period of <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dc_c20220101__20220331__srt--TitleOfIndividualAxis__custom--EmployeesMember_z5aJ1GWz1KFe" title="Expected term">five years with immediate vesting. The weighted-average fair value attributable to options granted in 2022 was $<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20220331__srt--TitleOfIndividualAxis__custom--EmployeesMember_zCB1bev22tra" title="Weighted-average grant date fair value">0.0208. The fair value of the stock options recognized in the period has been estimated using the Black-Scholes option pricing model. Assumptions used in the pricing model are as provided below. SCHEDULE OF FAIR VALUE OF STOCK OPTION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220101__20220630_zULo2Qxk5YS" style="width: 16%; text-align: right" title="Risk-free interest rate">1.55</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20220630_zf0gQrHQQ917" style="text-align: right" title="Exercise price">0.0518</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220101__20220630_zCPmGHlbp5qg" style="text-align: right" title="Expected volatility">44.12</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_c20220101__20220630_zE0Qo3fHccyi" style="text-align: right" title="Expected dividends">-</td><td style="text-align: left"> </td></tr> </table> The Company recognized a equity incentive expense of $243,435 for the six months ended June 30, 2022. As of June 30, 2022, there were 7,456,500 fully vested options outstanding with a weighted average exercise price of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20220630_zejjtsTqyjpg" title="Weighted average exercise price, granted">0.0518 per share. There were no non-vested options outstanding. A summary of the Company’s stock option plan and changes during the six months ended June 30, 2022 is as follows: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Balance - beginning of the year</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20220630_z6MCLfmO937b" style="text-align: right" title="Number of options, Beginning balance">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220630_zKJsAU0zLok8" style="text-align: right" title="Weighted Average Exercise Price, Beginning Balance">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20220630_zJxt2vDYIalj" style="width: 16%; text-align: right" title="Number of options, Granted">7,596,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20220630_zpADG5f9miuf" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Granted">0.0518</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20220630_z5AFfJRSle6a" style="text-align: right" title="Number of options,Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20220630_zzsxWYHynnK3" style="text-align: right" title="Weighted Average Exercise Price,Exercised">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20220101__20220630_z3mxTUVLoulg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, Cancelled">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20220630_zqniEVQLa6Y3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Cancelled">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance - end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20220630_ztsOcbjoSS2i" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Ending Balance">7,596,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20220630_zF8URhYryk1e" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Ending Balance">0.0518</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The aggregate intrinsic value of vested share options (the market value less the exercise price) at June 30, 2022 was zero. Curative Biotechnology, Inc Notes to Condensed Financial Statements (Unaudited)

1000000

7456500

0.0518

P5Y

0.0208

Assumptions used in the pricing model are as provided below. SCHEDULE OF FAIR VALUE OF STOCK OPTION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220101__20220630_zULo2Qxk5YS" style="width: 16%; text-align: right" title="Risk-free interest rate">1.55</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20220630_zf0gQrHQQ917" style="text-align: right" title="Exercise price">0.0518</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220101__20220630_zCPmGHlbp5qg" style="text-align: right" title="Expected volatility">44.12</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_c20220101__20220630_zE0Qo3fHccyi" style="text-align: right" title="Expected dividends">-</td><td style="text-align: left"> </td></tr> </table>

0.0155

0.0518

P5Y

0.4412

243435

7456500

0.0518

A summary of the Company’s stock option plan and changes during the six months ended June 30, 2022 is as follows: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Balance - beginning of the year</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20220630_z6MCLfmO937b" style="text-align: right" title="Number of options, Beginning balance">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220630_zKJsAU0zLok8" style="text-align: right" title="Weighted Average Exercise Price, Beginning Balance">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20220630_zJxt2vDYIalj" style="width: 16%; text-align: right" title="Number of options, Granted">7,596,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20220630_zpADG5f9miuf" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Granted">0.0518</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20220630_z5AFfJRSle6a" style="text-align: right" title="Number of options,Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20220630_zzsxWYHynnK3" style="text-align: right" title="Weighted Average Exercise Price,Exercised">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20220101__20220630_z3mxTUVLoulg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options, Cancelled">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20220630_zqniEVQLa6Y3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Cancelled">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance - end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20220630_ztsOcbjoSS2i" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Ending Balance">7,596,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20220630_zF8URhYryk1e" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Ending Balance">0.0518</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

7596500

0.0518

7596500

0.0518

NOTE 11 - FINANCIAL INSTRUMENTS (a) Liquidity Risk Liquidity risk is the risk that the Company will not be able to meet its obligations associated with financial liabilities. The Company relies on cash flows generated from operations, as well as injections of capital through the issuance of the Company’s capital stock to settle its liabilities when they become due. (b) Interest Rate Risk The Company is not exposed to significant interest rate risk due to the short-term maturity of its monetary assets and liabilities.

NOTE 12 - IMPAIRMENT OF LONG LIVED ASSETS In the fourth quarter 2021 the Company determined that its fixed assets were obsolete and wrote off the undepreciated balance of $1,958. In March 2021, when the Company’s new website was placed in service, the remaining unamortized cost of the Company’s legacy website was written off, for a total charge of $15,000.

1958

15000

NOTE 13 - COMMITMENTS AND CONTINGENCIES (a) Other The Company is subject to asserted claims and liabilities that arise in the ordinary course of business. The Company maintains insurance policies to mitigate potential losses from these actions. In the opinion of management, the amount of the ultimate liability with respect to those actions will not materially affect the Company’s financial position or results of operations.

NOTE 14 - CONCENTRATIONS OF CREDIT RISK (a) Cash The Company maintains its cash in bank deposit accounts, which may, at times, may exceed federally insured limits. The Company had zero and $416,178 cash balance in excess of FDIC insured limits at June 30, 2022 and December 31, 2021, respectively.

416178

NOTE 15 - COVID-19 PANDEMIC AND VARIANTS The full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial condition, will depend on future developments that are uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements, and although there is currently no major impact, there may be changes to those estimates in future periods.

NOTE 16 - SUBSEQUENT EVENTS (a) Convertible Senior Secured Note Payable and Warrants In August 2022, The Company and the lender agreed to a modification of the Note. In exchange for a one month extension to begin the principal payments under this Note, the parties agreed to reduce the qualified offering amount from $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20220831__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleSeniorSecuredNotePayableAndWarrantsMember__us-gaap--LineOfCreditFacilityAxis__custom--LenderMember__srt--RangeAxis__srt--MaximumMember_z6RQABK0FmS" title="Debt instrument, face amount reduce">10 million to $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20220831__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleSeniorSecuredNotePayableAndWarrantsMember__us-gaap--LineOfCreditFacilityAxis__custom--LenderMember__srt--RangeAxis__srt--MinimumMember_zVmud2sH7Cd9" title="Debt instrument, face amount reduce">7.2 million; <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDateDescription_c20220829__20220831__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleSeniorSecuredNotePayableAndWarrantsMember__us-gaap--LineOfCreditFacilityAxis__custom--LenderMember_zfA0UHEvZ0j2" title="Debt instrument maturity description">modify the payment schedule from seven (7) months to six (6) months. In addition, the lender received <span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20220831__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleSeniorSecuredNotePayableAndWarrantsMember__us-gaap--LineOfCreditFacilityAxis__custom--LenderMember_zeeQRKWXWbpf" title="Number of warrant received">1,904,762 additional warrants having a fair value of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220829__20220831__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleSeniorSecuredNotePayableAndWarrantsMember__us-gaap--LineOfCreditFacilityAxis__custom--LenderMember_zrdQQi2Rdq37" title="Number of warrant value">58,884, which will be recorded as an additional debt discount and amortized over the remaining life of the Note.

10000000

7200000

modify the payment schedule from seven (7) months to six (6) months.

1904762

58884

Series A and Series C Preferred Stock amounts reflected in mezzanine equity